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1. Abstract 
 
Novel medical implant materials are in increasing demand. Conventional implants can fail due to lack 
of proper integration into host tissue or due to bacterial infections. Microbial implant infections are a 
significant clinical problem due to their resistance to conventional antibiotics. There is a need of 
dedicated implant materials with improved biological properties. Novel biomaterials or implant 
coatings need to be tested in vivo before going to clinics. Traditionally, histology was used to evaluate 
tissue interactions of implant materials but this method requires animal sacrifice and only a single time 
point can be analyzed. Here, we developed in vivo models that have the ability to distinguish 
inflammatory implant material responses from the wounding responses and from bacterial infections. 
Non-invasive imaging was used for visualization and quantification of biomaterial induced 
inflammation. Initially, reactive products of inflammation such as reactive oxygen species, proteases 
and inflammatory cell growth stimulatory molecules were visualized using fluorescent imaging. With 
these approaches, highly inflammatory materials could be differentiated from the biocompatible 
implants. However, the technique suffered from high background and from autofluorescence of tissue. 
For this reason, adoptively transferred bioluminescent immune cells were used to evaluate the 
inflammatory potential of implant materials. Immune cells were isolated from luciferase expressing 
murine bone marrow. The luminescence was controlled by a promoter with a high basal activity that 
was further stimulated by bacterial infections that enabled to visualize and quantify the luminescence 
of immune cells at the site of inflammation in vivo. Several materials of different inflammatory 
potential were tested.  Inflammatory and infected biomaterials showed a clear difference in signal 
intensity when compared to biocompatible materials or injury. The highest signal was observed from 
infection. Polystyrene and the wound suture material poly lactic-co-glycolic acid (PLGA) implants 
acted inflammatory in this assay. The results were validated by using histology. Thus, bioluminescent 
immune cells provided a non-invasive, reliable and sensitive readout that correlated with the 
inflammatory potential of materials. This method may be used for evaluating the inflammatory 
potential of new implant materials or implant coatings and may be further developed as method for 
early detection of implant infections in the clinic.   
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2. Introduction 
 
2.1 Biomaterials and their importance in health care 
 
Biomaterials are part of medical devices or implants that are introduced into host tissue for replacing 
or enhancing natural function of damaged tissue or organ. Over fifty years, biomaterials have been a 
part of medicine and are employed in the fabrication of simpler implants such as intraocular lenses to 
more complex structures like biosensors, pacemakers and total artificial heart. These devices can not 
only extend the life span of patients but also improve the quality of life. The use of medical devices 
has increased over the last decade. In United States, the demand for medical devices increases by 7.7% 
every year [1]. The most commonly used are orthopedic and cardiovascular implants. The implanted 
biomaterial must be biocompatible and able to support replaced or enhanced function of tissue or 
organ for longer period of time. Therefore, the development of a suitable biomaterial involves 
integrated innovations in materials and biological sciences. 
  
The primitive materials used for fabrication of implants were of natural origin such as tooth implants 
made of ivory and gold. Then, industrial materials were developed with improved mechanical and 
physiological properties. The desirable property of a material largely depends on its application in the 
host. For example, hip implants are subjected to high levels of mechanical stress and hence should be 
strong and rigid whereas vascular grafts should be flexible and less strong. For pacemakers, the 
important properties of the material are its electrical and thermal conductivity and light transmission 
[2]. In 1990s, due to the introduction of tissue engineering, the paradigm of material shifted to use of 
scaffolds. Scaffolds are artificial structures that can -support three dimensional growth of tissue. These 
structures provide suitable niche to cells by supporting their survival and proliferation in the host and 
after serving the purpose, scaffold has to degrade by hydrolysis or enzymatic digestion [3]. Another 
breakthrough in the field of biology was stem cell research in early 2000s, where the power lies in the 
human cells to regenerate the tissue and restore the function. This challenged the role of existing 
biomaterials and urged the need of novel materials that can perform signaling functions to instruct the 
local cellular processes [4].    
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Table 1: Examples of biomaterials and their medical applications [5]  
 
Application Biomaterials 
Joint replacements Stainless steel, titanium, polyethylene 
Pacemakers Titanium, polyurethanes 
Intraocular lenses Poly (methyl methacrylate)  
Cochlear implants Platinum, silicone 
Artificial heart valves Dacron, carbon, metal  
Catheter  Silicone rubber 
Dental implants Titanium, Alumina, Hydroxyapatite 
Breast implants Silicone 
Stents Stainless steel 
Artificial tendon or ligament Polyester fibers 
Sutures Polylactic acid 
 
2.1.1 Generation of biomaterials 
 
To understand the evolution of biomaterials, the iterative process was categorized into three 
generations of materials. Biomaterials in each generation represent the evolution of requirements and 
properties of materials. 
  
In the first generation of biomaterials (ancient-1940), the implants were prepared by using mostly 
available industrial materials such as metals and cobalt chrome alloys with the intended use of 
replacing damaged or diseased tissue with minimum immune responses in the host. Metallic implants 
were used by ancient Egyptian and Etruscan civilizations for fixing fractures or other skeletal injuries 
[6]. Some civilizations also used gold plates to fix broken bone which was evident from the skull 
found in Peru corresponding to 2000 BC [7]. In 1886, Hansmann was the first surgeon to introduce 
metallic plates and screws for the bone. He performed a surgery where he repaired the fracture by 
fixing the bone using metal plate and screws [8]. Early 20th century saw an increased use of metals in 
orthopedic implants. Cobalt-based alloys were used in orthopedic surgery because of its low level of 
corrosion and these alloys still have their applications in orthopedics [9]. In 1940s, titanium was 
studied in vivo and was found to be biocompatible along with good integration in the bone. Since then, 
titanium was investigated in depth and was proposed to be used in dental implants [10]. Apart from 
metals, ceramics and polymers were also used as biomaterials. For example, the first artificial kidney 
was transplanted by using the hemodialyzer made of cellophane tubing [11]. The intraocular lens used 
for treatment of cataract was made of polymer, poly(methyl methacrylate) in 1948 [12]. The goal of 
biomaterials during this period was focused on inertness of the materials.  
 
The second generation of biomaterials (1980-2000) was focused on development of materials that 
are not completely inert but able to induce a controlled specific response in the physiological 
environment. For example, the use of hydroxyapatite (HA), a natural mineral of the bone, supports 
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bone ingrowth and osseointegration while placed in bone tissue [13]. Synthetic hydroxyapatite was 
used as porous implants, powder or coatings on the maxillofacial and dental implants. These coatings 
provided a bioactive interface and promoted the osteoconduction process. Studies have shown that 
titanium implants with HA coatings had greater bone contact when compared to the uncoated implants  
[14]. Other most commonly used biomaterials were resorbable polymers that degrade in physiological 
environment in a controlled manner. For example, drug eluting stents were manufactured by 
resorbable polymers to avoid the problem of stenosis in the coronary arteries [15]. After reaching a 
saturation point in the first and second generation of biomaterials, it was realized that a shift towards 
more biological based methods was essential. 
 
The third or present generation of biomaterials (2000-present) exposes novel materials and their 
applications in medicine but they are not meant to replace materials of the first generation. The 
biomaterials of third generation are tailored to stimulate cellular responses specific to their application. 
Resorbable scaffolds are designed to support proliferation and differentiation of embedded progenitor 
cells into desired tissue. This artificial system is implanted in the patient where tissue integrates in the 
host and scaffolds are resorbed. The development of artificial tissue to replace or enhance diseased 
tissue function is known as tissue engineering [3]. The other way to orchestrate such tissue growth is 
by using bioactive materials that release ions or embedded growth factors, thereby stimulating the 
cells in contact. Recent in vitro studies have shown that bioactive glasses genetically control the 
cellular responses of osteoblasts. A set of genes in the osteoblasts were upregulated upon exposure to 
bioactive glass. These genes express proteins involved in differentiation and proliferation of the cells 
[16].   
 
The three generations represented an evolutionary picture of mechanical, chemical and biological 
properties of biomaterials. Coming years would expect a further increase alongside more sophisticated 
and greater reliable biomaterials.  
 
In the coming chapters, the study has been divided into three major categories to develop a 
background. The first section gives an overview of biocompatibility of different materials and then 
moves to available biocompatibility testing methods. The second chapter highlights immune response 
to biomaterials explaining the signals induced by inflammatory cells and tissue cells in response to 
materials and also possible strategies to modulate inflammation. The third chapter gives an overview 
of infections on implants and mechanism of bacterial colonization in brief.  
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2.2 Biocompatibility 
 
Biocompatibility is a general term extensively used for all biomaterials. In 1987, biocompatibility was 
defined as ‘‘the ability of a material to perform with an appropriate host response in a specific 
situation’’ [17]. Each biomaterial has its individual tissue interaction and the definition proposed 
seemed to be generalized. However, due to diversity in the materials and their host responses, a 
different paradigm of biocompatibility was evolved [18]. In addition to the characteristics of materials, 
there are several other parameters of  biocompatibility such as the site of application of biomaterial, 
clinical intervention during implantation surgery, the recipient of implant (age, sex and general 
health), the design of biomaterial and its interaction with host, the presence of microbes on implants 
and the presence of endotoxins produced by microbes [19-21].  
 
The biocompatibility essentials of a material used to design an implant depends upon their application. 
For instance, if the implant is intended for long term applications then the most desired properties to 
approve it as biocompatible would be 1) minimal production of wear particles 2) minimal tissue 
response 3) minimal disturbance of homeostasis [22, 23]. Similarly, other long term implants such as 
breast implants need additional biocompatible features like minimum fibrosis around the material to 
allow the development of glandular and fatty tissue. Silicone gel in combination with silicone 
elastomeric shells were used as breast implants providing the consistency, size and shape [24]. This 
shows customized list of biocompatibility features of implants depending on their application site. One 
should not forget the standards of biocompatibility for degradable implants where the pressure on the 
materials is not only to perform but also to degrade and eliminate from the body after its performance 
with minimum tissue reaction. The process of degradation leads to production of side products, which 
are capable of stimulating immune response, therefore, the material can be classified as biocompatible 
only if the response is clinically acceptable. Polyester sutures degrade within 3-12 weeks and the 
degradation products are physiologically acceptable [22, 25]. The other clinical use for biodegradable 
polymers is in drug delivery where they can be used in the form of microspheres or coatings on 
metallic implants. The tissue response to microspheres follow the sequence of inflammation from 
acute, sub-acute and chronic until the microspheres disappear from tissue either due to resorption or 
phagocytosis by macrophages [22, 26]. The biocompatibility of microspheres not only depends on the 
degradation rate and degradation products but also on the size of microspheres. The fundamental shift 
in the understanding of the biocompatibility was when tissue engineering was introduced in which 
regeneration ability of the cells was exploited. Cells can be stimulated to grow into tissue in a 
controlled fashion ex vivo or in vivo. Biomaterial is used either to impart the shape or to provide the 
mechanical stability to the cells, referred to as scaffold or matrix, which ideally should elicit an 
appropriate response [22, 27]. Hence, considering the variations or diversity in the materials and their 
applications biocompatibility was redefined by Williams as –  
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‘‘ Biocompatibility refers to the ability of a biomaterial to perform its desired function with respect to 
medical therapy, without eliciting any undesirable local or systemic effects in the recipient or 
beneficiary of that therapy, but generating the most beneficial cellular or tissue response in that 
specific situation, and optimizing the clinically relevant performance of that therapy [22].’’ 
2.2.1 Biocompatibility testing  
 
Novel implant materials are tested for their biocompatibility before going into clinics. There are 
traditional standard in vitro and in vivo test systems to study interaction of implant materials with cells 
and tissue.  
2.2.1.1 In vitro biocompatibility tests 
 
The International Organization for Standardization (ISO) 10993-5 sets up standard in vitro testing 
protocols which should include positive and negative controls of the materials, the tests should be 
performed not only with the materials directly but also with material extracts. Appropriate cell lines 
and cell media should be used [28]. For instance, primary rat osteoblast cell culture is a standard to 
study the parameters supporting formation and mineralization of the extracellular bone matrix [29-31]. 
In vitro tests are cheaper, sensitive, reliable, convenient and reproducible compared to in vivo testing 
[32, 33]. Additional in vitro tests to evaluate the cytotoxicity, carcinogenesis/mutagenesis and cell 
functions are established [32-36]. For cytotoxicity testing, MTT (3-(4,5-dimethylthiazo-2-yl)-2,5-
diphenyltetrazolium bromide) assay is used in which MTT compound is reduced by the mitochondrial 
enzyme of living cells and after reduction it converts into formazon, a colored water insoluble 
compound. The amount of produced formazon is recorded using a spectrophotometer which can be 
correlated to the living cells [28]. Another test is the Ames test, which evaluates the mutagenesis using 
bacterium Salmonella typhimurium with a mutated gene and this mutation disables the bacterium to 
generate amino acid histidine from culture medium. In presence of a mutagenic agent, this mutation 
can revert back to regain the ability to synthesize histidine. Mutagenicity is assessed by growing the 
bacterium in the presence of material extracts [28]. 
2.2.1.2 Animal test models to evaluate the biocompatibility of biomaterials 
 
Animals used for the biocompatibility studies depend upon the type of implants such as cochlear 
implants in kittens [37], orthopedic implants in sheep or pigs [38] and dental implants in rats [39]. 
Larger animals are used to monitor the functionality and biocompatibility of biomaterials. One of the 
limitations of using larger animals in the study is need for bigger storage space and their breeding in 
pathogen free conditions. Secondly, with the development of novel biomaterials, there is a need of a 
reliable screening system to evaluate their biocompatibility with minimum usage of animals. For this, 
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the study shifted to mouse or rat models due to its 1) similarity to humans [40] 2) convenient in house 
breeding under pathogen free conditions 3) minimum storage space.  
 
Conventionally, the cage implant model in rats was established to monitor inflammatory reactions in 
response to glucose sensors [41]. The biomaterial is placed inside the cage of stainless steel and is then 
implanted in rats; the exudate can be collected from cage without sacrificing the animal [42-44]. 
Glucose sensors were tested in this model and antibodies in response to the biomaterial were checked 
to characterize immune response [41]. However, the cage model does not involve direct interaction of 
the tissue and only exudates can be examined.  
 
Numerous other mouse models have been established to evaluate the biocompatibility of implants 
using in vivo imaging techniques. Recent publications have demonstrated the development of 
fluorescent or luminescent reporter molecules that can detect inflammatory reactive oxygen species, 
nitric oxide, proteases and hydrogen peroxide in vivo. Implant related inflammation was imaged non-
invasively using near infra-red fluorescent hydrocyanines that can image reactive oxygen species [45]. 
Hydrocyanines are the reduced form of commercially available cyanines which becomes fluorescent 
when encounter reactive oxygen species [45]. Other, fluorescent reporter molecules such as 
diaminocyanine sulfate specific to nitric oxide were generated to detect implant associated 
inflammation [46]. Recently, luminol (5-amino-2,3-dihydro-1,4-phthalazinedione) and its analog L-
012 were used to detect oxygen radicals in response to inflammatory materials [47, 48]. L-012 and 
luminol are chemiluminescent probes, whereby L-012 was found to be more sensitive and specific for 
oxygen radicals [49-51]. Several other strategies were followed to monitor the device associated 
inflammation such as peroxalate nanoparticles used to detect hydrogen peroxide [52, 53]. The other 
method to monitor inflammatory response is to target the proteolytic enzymes such as cathepsins, 
secreted by neutrophils and macrophages as part of immune reaction in response to the implants. For 
this, a commercially available fluorophore by Perkin Elmers, Prosense 680 targeted the produced 
cathepsins in response to inflammatory implants [54]. However, these inflammatory reporter 
molecules are not used as standards to evaluate biocompatibility of implant materials.  
 
The immune response to implants is studied extensively but still there is no standard mouse model that 
can be used for evaluation of implant-tissue interactions. The immune response to implant materials is 
a dynamic process that involves complex signaling between immune cells and tissue cells. The next 
chapter will provide step-wise explanation of immune response to implant materials. 
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2.3 Wound healing and inflammatory response to biomaterials 
 
Immune reaction in response to implanted biomaterial is a series of sequential events starting from the 
injury caused due to implantation procedure. Soon after implantation, proteins from the blood and 
interstitial fluid are adsorbed on the surface of biomaterial. The layered protein surface on the 
materials serves as provisional matrix for inflammatory cells. Injury also plays a role in attracting and 
activating the immune cells. The first cells to arrive at the implantation site are the circulating 
polymorphonuclear leukocytes that release granular enzymes. The inflammatory response can become 
chronic. Macrophages can adhere to the biomaterial surface and then fuse to form a foreign body giant 
cell. These giant cells secrete large quantities of degradative enzymes impairing wound healing 
process and leading to failure of implanted device. As a part of wound healing, macrophages and 
endothelial cells also secrete pro-fibrotic factors promoting the formation of a fibrous capsule 
surrounding implant. The thickness of the fibrous tissue surrounding the implant depends upon the 
immunogenicity of biomaterial. Excessive fibrosis can lead to loss of functionality of implant, for 
example, fibrosis on coronary stents block the blood flow of arteries and then the device needs to be 
removed from the patient [55-58].  
 
To make the mechanism understandable, the immune response will be discussed at each step. First 
step is the formation of protein layer on implant surface. These proteins have a major influence on the 
inflammatory response to biomaterials. 
2.3.1 Adsorption of proteins 
 
As soon as the implant comes in contact with the host tissue, proteins from blood and interstitial fluids 
are adsorbed on the surface of implants. The acquisition of a protein layer occurs in nanoseconds (Fig. 
1). This affects the interaction of implant with tissue. Adsorbed protein layer provides a provisional 
adhesion matrix to inflammatory cells or other cell types [59]. For example, osteoblastic cells are 
found to be dependent on the adsorbed fibronectin or vitronectin for adhesion and proliferation on 
polystyrene cell culture plates, titanium, stainless steel and hydroxyapatite in vitro [60-62]. The 
surface properties of the materials also decide the type, concentration and orientation of the proteins. A 
difference has been observed in the adsorption rates of proteins on hydrophobic and hydrophilic 
surfaces. Hydrophilic materials such as titanium and hydroxyapatite exhibited superior abilities to 
integrate in the bone [63-66]. However, the surface charge of the material also showed different 
degrees of adsorptions of proteins but the effect was not as profound as in case of hydrophilic surfaces. 
In the absence of cellular interactions, adsorbed proteins can be replaced by proteins exhibiting higher 
affinity to the material surface, this phenomenon is known as Vroman effect [67]. Moreover, 
fibronectin and vitronectin adhesion protein could support macrophage adherence and formation of 
foreign body giant cells in vitro [68, 69]. This means that adsorbed proteins on the biomaterial surface 
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may influence the wound healing or inflammatory response [70]. The differential protein-mediated 
biomaterial cell interactions can be intervened therapeutically to enhance the integration of biomaterial 
into tissue. 
2.3.1.1 Role of coagulation and complement proteins 
 
Injury or mechanical damage to cells is associated with the implantation procedure. Injured blood 
vessels activate intrinsic and extrinsic coagulation pathways by producing initiators of the coagulation 
system; Factor XII (FXII) and tissue factor respectively [71]. Studies have shown that FXII gets 
activated by contact with the negatively charged surface of biomaterials that activates a cascade of 
proteins eventually releasing thrombin. The released thrombin is not sufficient to produce clots but 
activates platelets. Activated platelets release mediators of the coagulation cascade. Eventually, 
proteins of the extrinsic pathway become activated by accumulating on the activated platelets [72]. 
Thrombin is generated in large amounts that cleave the fibrinogen to fibrin. Deposited fibrin forms a 
primary mesh or clot around the biomaterial which is in turn is sensed by phagocytes, thus initiating 
inflammatory response (Fig. 1) [73, 74]. As a result, blood coagulation on biomaterials is a combined 
effect of contact activation and platelet activation [70, 75-78]. 
 
 
 
Figure 1 : Priming of immune cells: Proteins from blood adsorb on the surface of biomaterials preparing 
adhesion matrix for cells. In parallel, injury stimulates coagulation pathway that activates platelets and 
eventually fibrin is formed that forms a mesh surrounding the biomaterial. Activated platelets also prime 
inflammatory cells. Complement proteins produce toxins (C3a and C5a) through classical and alternative 
pathway that leads to priming of immune cells. C stands for complement proteins and PMNS are 
polymorphonuclear leukocytes. Modified from [70] 
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The complement system is a part of innate immunity. It constitutes small proteins present in blood in 
inactive state. The complement system gets activated by foreign surfaces by three different pathways, 
the classical, the alternative and the lectin pathway. All the pathways produce C3 convertase enzyme 
that leads to the release of toxins C5a and C3a. Biomaterial-associated complement activation largely 
depends on the classical and the alternative pathways [70, 79-81]. Adsorbed proteins on the implant 
includes IgG molecules that engages C1q (complement protein) and forms the C1 protein complex 
which is the first enzyme of the classical pathway [82]. Moreover, C3 protein can directly adsorb on 
the surface of biomaterial and activate the alternative pathway [83]. As a result, the initiating C3 
convertase enzyme is generated which further amplifies the loop by producing more mediators. Once 
sufficient enzyme is produced, it promotes the release of pore forming toxins C3a and C5a. These 
toxins have multiple functions such as priming granulocytes and monocytes, inducing the release of 
reactive oxygen species by granulocytes, triggering mast cell degranulation and increasing vascular 
permeability of the cells (Fig. 1) [84].  
 
The coagulation and complement pathway function synergistically on the biomaterial surface to 
promote the inflammatory responses [85]. Fibrinogen, factor X, iC3b, fibronectin and vitronectin were 
shown to be adsorbed on the biomaterial surface [86]. These proteins are known as the ligands for 
receptors of the inflammatory cells. The receptor ligand binding promotes the adherence of the 
inflammatory cells to the surface and subsequently activates them.  
2.3.2 Danger signals recognized by polymorphonuclear leukocytes (PMNs) 
 
Alternatively, injury due to implantation surgery can also activate the inflammatory cells. Injured 
tissue releases danger molecules or alarmins which are recognized by a set of receptors of the 
polymorphonuclear leukocytes leading to their activation (Fig. 2). Apart from the pathogens, trauma is 
one of the causative agents of cell and tissue damage. Alarmins are endogenous molecules released by 
dying cells. Inflammatory cells recognize these molecules through special receptors and promote the 
innate and adaptive immune responses [87]. The most common example of alarmins is HMGB1 (High 
mobility group box 1) which is a nuclear protein with a DNA binding domain [88]. During non-
programmed cell death, this protein is passively released [89, 90]. Recent studies have shown that 
those macrophages engulfing apoptotic cells also secrete HMGB1 [91]. It also acts as signaling protein 
and helps in migration of monocytes, macrophages, dendritic cells and neutrophils [92-94]. There are 
some calcium binding proteins that behave as alarmins during inflammation like S100 proteins, these 
proteins are expressed by phagocytes [95]. Heat shock proteins (HSPs) are secreted by necrotic cells 
and they mediate the release of inflammatory signaling molecules by binding to cells of the innate 
immune system [96]. Alarmins evoke immune response by binding to receptors of immune cells. This 
receptor-ligand binding activates signaling pathways of innate immunity.   
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Table 2: Examples of alarmins and their functions [87] 
 
Alarmins Origin Physiological 
function 
Target 
receptors 
Extracellular function 
HMGB1 All cell types Transcription 
regulator 
RAGE 
TLR2 
TLR4 
- Pro-inflammatory 
cytokines 
- Activation of platelets 
- Chemotactic activity 
S100A8/A9/A12 Phagocytes 
Epithelial 
cells 
Calcium 
homeostasis 
RAGE 
 
- Pro-inflammatory 
immune response 
- Release of neutrophils 
from bone marrow 
- Increases vascular 
permeability 
Heat shock 
proteins, HSP60 
and HSP70 
All cell types Assist protein 
folding 
TLR2/TLR4 - Release of pro-
inflammatory 
cytokines 
- Imuunostimulation of 
natural killer cells 
 
 
Figure 2: Immune response to implants: Sequential events triggering the immune response after implantation, 
proteins from the blood and the interstitial space are adsorbed on the surface of the implants. PMNs reach to the 
site of implantation and get activated by recognizing alarmins released from the injured tissue through receptors 
and initiate the secretion of reactive oxygen species and proteases. Prolonged activation of PMNs leads to the 
release of signal proteins that recruit monocytes and macrophages to the inflammation site. Modified from [70] 
 
Polymorphonuclear leukocytes (PMNs) form the first line of defense and are the first cells to arrive at 
the site of inflammation. Following injury and protein adsorption, PMNs migrate from blood to the 
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implantation site rapidly. They sense injury because of alarmins released by injured tissue, activated 
platelets and endothelial cells. PMNs recognize protein coated implant surface and bind to the bound 
proteins by engaging their transmembrane receptors that promote cell-cell interactions or cell-
extracellular matrix interactions. The adherent cells sense damage by their receptors. This recognition 
triggers phagocytic activity of the cells [70, 97, 98]. The cells start to release certain proteases and 
reactive oxygen species to promote pathogen killing. Excessive production of oxygen radicals or 
proteases can corrode biomaterial surface, for example, polyurethane [99]. The production of 
destructive agents by PMNs also hinders integration of biomaterial into tissue by damaging the tissue 
and prolonging the inflammatory response. PMNs release molecules that signal to attract more 
inflammatory cells to the site of inflammation [100]. Within two days after implantation, PMNs 
disappear from the implantation site [86] (Fig. 2). 
2.3.3 Role of macrophages in wound healing and in biomaterial associated 
inflammation 
 
Monocytes and macrophages are guided to the implantation site in response to signal molecules 
released by granulocytes [70, 101]. Monocytes undergo phenotypic change and become macrophages 
in the tissue (Fig. 3). Macrophages are phagocytic cells that engulf cellular debris and foreign 
particles. They secrete cell signaling proteins called as cytokines in inflammation or wound healing 
that affects the behavior of immune cells. Based on function of macrophages, they are generally 
classified as classically and alternatively activated [102, 103]. Classically activated macrophages are 
inflammatory cells that induce production of inflammatory cytokines such IL-12, IL-6 and IL-1 and 
perform microbicidal activity by producing reactive oxygen species [70, 102, 103]. However, the 
alternatively activated macrophages are further subdivided into regulatory and wound healing 
macrophages [103]. Wound healing macrophages down regulate the inflammatory cytokines and 
promote tissue resolution by inducing the production of extracellular matrix or activation of fibroblasts 
[103, 104]. Regulatory macrophages can dampen inflammation by excessive production of IL-10 
which is a very strong immunosuppressive cytokine [70, 103]. The early phase of inflammation 
involves phagocytic and microbicidal activity of classical activated macrophages. Later, the wound 
healing macrophages become active and play crucial role in tissue resolution. It is still unclear that the 
macrophages already at the site of inflammation change their phenotype from one type to the other or 
they emigrate from the site [70]. The plasticity of macrophages makes them a potential target in 
immunomodulation therapy.  
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Figure 3: Formation of giant cells and fibrosis: Monocytes and macrophages are recruited in response to the 
signaling proteins released by PMNs. The recruited macrophages start fusing with each other in response to 
stimuli from other immune cells and they form multinucleated foreign body giant cell (FBGC). Giant cells 
produce proteases and oxygen radicals, eventually corroding the biomedical polymers. Fibroblasts proliferate 
and synthesize type 1 collagen which when produced in excess amounts can encapsulate the biomaterial. 
Modified from [70] 
2.3.4 Formation of foreign body giant cells and device failure  
 
Macrophages adherent to the biomaterial surface are classically activated and exhibit the pro-
inflammatory response by secreting reactive oxygen species, degradative enzymes and cytokines. 
They start phagocytosing particles up to size of 5 µm and upon encountering the particles bigger than 
this size (>10µm), macrophages fuse with each other to form foreign body giant cells (Fig. 3) [105]. 
Other immune cells signal the fusion of macrophages by secreting signaling proteins [106-108]. Fused 
cells are phenotypically closer to alternatively activated macrophages [103]. However, fused cells also 
start the frustrated phagocytosis phenomenon, according to which, fused macrophages have reduced 
phagocytic ability than adherent macrophages but their capacity to secrete degradative enzymes such 
as reactive oxygen species and protons is enhanced (Fig. 3) [109-111]. These giant cells can stay at the 
site of implant for longer period of time, but it is unclear whether they become inactive or persistently 
produce degradative enzymes. As a result, the degradative chemical environment at biomaterial-tissue 
interface may result in the degradation of biomaterials depending upon their surface properties of 
materials. Polymers are susceptible to degradation such as polyethylene used in artificial joints can be 
oxidized by the reactive oxygen radicals. Moreover, a device can also fail by cracking due to stress by 
adherent macrophages and foreign body giant cells, for instance, lead insulation of the pacemaker 
made up of polyether polyurethane cracked due to the environmental stress [112, 113].  
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2.3.5 Fibrosis 
 
Fibrosis is the last phase of wound healing process [114]. Foreign body giant cells release the 
destructive agents in the tissue material interface, impairing the wound healing response [57, 115]. 
Macrophages, endothelial cells, lymphocytes and fibroblasts themselves, produce profibrotic factors 
which triggers the continuous proliferation of fibroblasts and production of connective tissue, resulting 
in fibrosis. Other profibrotic factors such as macrophage derived growth factors and fibroblast 
activating factors (FAFs) also upregulate the synthesis of type I and type II collagen which are 
extracellular matrix proteins [116]. The continuous proliferation of fibroblasts and production of 
collagen fibrils may encapsulate the biomaterial surface and the functionality of the device may fail 
(Fig. 3). 
 
2.4 Strategies to improve the interaction of biomaterial with tissue and 
modulation of inflammatory responses 
 
To improve the implant tissue interaction, specific cell responses can be promoted by modifying the 
surface of biomaterials [117]. For instance, titanium is an inert material with several biological 
applications as implants. The properties of titanium can be improved by modifying the surface in a 
way that allows migration, and adhesion of bone forming cells, hence enhancing the osseointegration  
[118]. Several strategies have been employed either by changing the physiochemical properties of the 
biomaterials or incorporating molecules or matrices to the surface of biomaterials influencing function 
of cells. 
2.4.1 Surface modifications of biomaterials 
 
The type and orientation of proteins adsorbed on biomaterial surface depend on the surface chemistry 
of material. The protein layer may enhance adhesion of immune cells by providing ligands to their 
receptors [59]. Modulating this protein layer on the surface of biomaterial could trigger desired 
functions of macrophages and PMNs. This strategy is categorized as passive modulation of immune 
responses to biomaterials. Proteomic analysis of macrophages cultured on different surface chemistries 
of polymers, hydrophilic, hydrophobic or anionic, revealed differential protein expression profiles 
[119, 120]. The amendments in the surface chemistry and topography of biomaterial also showed 
changes in macrophage responses. Natural extracellular matrix components imprinted at micron or 
nano scale on the surface of materials have the ability to direct cellular responses, increasing the 
adhesion, spreading, migration and proliferation of target cells  [121, 122]. Parallel gratings were 
imprinted on different polymers and it was observed that independent of the surface chemistry of 
material, these induced topographic changes affected macrophage morphology and function in vitro 
and adhesion of macrophages to the surface in vivo [123]. 
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2.4.2 Biological functionalization of implant materials by using bioactive molecules 
 
The performance of material could be improved by optimizing biological properties at the surface of 
implant material to improve interaction with the host tissue. The material - tissue interactions can be 
augmented by local and long long-lasting delivery of biological agents that can be either therapeutic or 
can enhance adhesion of only desired cells to the surface. Bioactive molecules are pharmacologically 
active agents that are either derived from natural sources or chemically synthesized. Immobilizing 
bioactive agents such as integrin adhesion sites, growth factors or anti-inflammatory drugs on the 
surface of biomaterials directs desired cellular responses. Short oligopeptide sequences of receptor 
binding domains for immune cells were synthesized and immobilized on the biomaterials, enhancing 
adhesion of specific cells [124, 125]. The domains of fibronectin RGD (arginine-glycine-aspartate) 
and PHSRN (proline-histidine-serine-arginine-asparagine) attached on the biomaterial regulated 
macrophage functions in vitro and in vivo [126, 127].  
 
Alternatively, anti-inflammatory drugs could be incorporated on the surface of biomaterials. For 
instance, glucocorticoids are potent immunosuppressive agents that trigger the downregulation of 
inflammatory signaling proteins, proteases and reactive oxygen species while up regulating anti-
inflammatory mediators to promote tissue resolution [128]. Another most commonly used anti-
inflammatory drug is dexamethasone that reduces the number of PMNs at the site of implantation in 
the initial phase of inflammation. At the chronic stage, presence of dexamethasone reduces 
macrophage number and fibrous capsule formation. Dexamethasone may also delay wound healing 
process [129, 130]. Biomaterials are required to supply dexamethasone throughout its survival time as 
the reduced effect will lead to infiltration of inflammatory cells thus increasing the immune response 
[131]. 
 
Growth factors may primarily affect tissue cells but are capable of modulating immune response. A 
tight cross talk between the inflammatory cells and tissue cells has been observed during wound 
healing and inflammation [132]. Fibroblasts regulate the production of inflammatory or anti-
inflammatory signaling proteins to maintain the homeostatic balance [133]. In tissue remodeling the 
mutual interaction of monocytes and fibroblasts has been observed [134]. Some growth factors can 
directly modulate the migration of macrophages during wound healing process. Therefore, 
immobilizing growth factors may directly or indirectly modulate the activity of monocytes or 
macrophages, hence improving the integration of biomaterial into tissue.  
2.4.3 Artificial extracellular matrix design 
 
Alternatively, researchers designed artificial matrices that can be used alone or as coating on the 
biomaterial surface to support specific cellular processes. These matrices could very well extrapolate 
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in vivo situation at the implant – tissue interface due to their high similarity to natural extracellular 
matrix. As we know, there is an extracellular space in the human tissues in which cells release 
biomolecules. These molecules help provide mechanical support to cells, in organization of the cells 
into tissues and controls the functions of cells to some extent [135]. Extracellular matrix (ECM) 
constitutes proteins and glycans. There are two classes of proteins present in the extracellular space, 
structural proteins such as collagen, elastin and proteins promoting cell adhesion, fibronectin or 
laminin [135, 136]. The most abundant protein is collagen that provides the tensile strength while 
elastin imparts elasticity to the ECM  [137]. Glycans are negatively charged, polysaccharide-rich 
substances filled in the spaces between the cells, for example, glycosaminoglycans (GAGs) and 
proteoglycans (PGs). They prevent the breakdown of tissue by filling aqueous spaces between protein 
fibrils in swollen state [135, 136, 138]. 
  
Tissue engineering matrices are currently designed to simulate the natural extracellular matrix that can 
provide several bioactive factors, essential for cell adhesion, spreading, proliferation and migration. 
Hydrogels are scaffolds used in tissue engineering due to high water content and its properties 
resemble soft tissues [139]. They are available as natural or synthetic hydrogels. Natural hydrogels are 
made of natural protein polymers such as collagen, fibrin or polysaccharides polymers (alginate, 
chitosan, hyaluronic acid and dextran) while synthetic hydrogels are synthesized using polymers such 
as poly (acrylic acid) (PAA), poly (ethylene glycol) (PEG), poly poly (vinyl alcohol) (PVA) or other 
polypeptides. Moreover, biomimetic hydrogels can be produced by grafting them with several bio-
functions such as decorating them with protein derived cell adhesive peptides to foster the cell 
adhesion process, incorporating growth factors to promote tissue regeneration and modulating its 
sensitivity to enzymatic degradation [139]. Although, hydrogels produced are known to be bio inert, 
but comparative studies demonstrated their immunogenic behavior depending upon their origin 
(natural or synthetic), handling methods or sterilization procedures, which limited their use [140]. 
 
Artificial extracellular matrix can also be generated by coating implants with proteins (eg. collagen) of 
extracellular matrix. Collagen coatings on titanium have shown to improve initial attachment of the 
bone cells [141]. Studies also demonstrated up-regulation of bone matrix proteins leading to bone 
remodeling around the collagen coated titanium implants [142]. Although collagen facilitated the 
initial attachment and spreading of bone cells it did not promote proliferation or differentiation of bone 
progenitor cells [143]. To this end, collagen matrices were prepared along with glycans GAGs and 
PGs, to mimic properties of natural ECMs. Proteoglycans (PGs) not only enhance the attachment of 
osteoblasts but also serves as mediators between the matrix and endogenous growth factors [144]. 
Sulfate groups in GAGs are identified as growth factor binding site in the natural ECM, hence 
artificially increasing the frequency of sulfate groups on GAGs may promote the tissue regeneration 
process. Chondroitin sulfate increases the sulfate groups on GAGs and the combination of collagen 
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with chondroitin sulfate improved the osteoconductive properties of titanium implants [145, 146]. 
Sulfated GAGs also modulate the immune response by promoting the binding of IL-10, a strong anti-
inflammatory cytokine, to monocytes or macrophages eventually enhancing the anti-inflammatory 
immune response [147, 148]. Therefore, the glycan of ECM acts passively or actively in modulation of 
the immune response and improving the tissue regeneration.  
 
Implant-related inflammation limits the function of implanted medical device. Therefore, it is essential 
that biomaterial integrates into tissue. Several approaches have been employed to modulate the 
inflammatory response by modification of the physiochemical properties or local delivery of bioactive 
agents to elicit the desired cellular response. The most promising approach is the design of the 
artificial extracellular matrices and due to their higher similarity to natural matrices they can regulate 
the immune response in a more specified and desirable manner.  
 
2.5 Implant – related infection  
 
Permanent or temporary implants usually face two challenges; inappropriate tissue integration and 
microbial colonization [149]. Implant surface is an attractive substrate for attachment and growth of 
microbes. When implants are introduced into a mammalian host, the tissue integration process 
competes with microbial colonization for the same surface, referred to “race for the surface” [149].  
The rapid integration of biomaterial into tissue minimizes the chances of bacterial colonization. This 
indicates that the implant should be highly biocompatible to promote wound healing process. 
However, in case of inferior bio-compatibility the immune system becomes compromised leading to 
delayed wound healing and bacteria can easily escape the immune reaction and may colonize the 
implant surface [149]. Studies have shown colonization of Staphylococcus epidermidis and 
Staphylococcus aureus on biomaterials [149-151]. Numerous other bacteria such as Pseudomonas 
aeruginosa, Proteus mirabilis, Escherichia coli and beta hemolytic streptococci also colonize medical 
implants [149, 150].  Pseudomonas aeruginosa caused bacterial keratitis by colonizing the used 
contact lens [152]. The mechanism of microbial colonization on medical implants has been delineated 
into several categories to make the process understandable [149].  
2.5.1 Biofilm formation on medical implants 
 
These steps closely represent in vitro mechanisms of bacterial biofilms formation, but very little is 
known about in vivo situation. The first step involves initial attachment of the bacteria on implant 
which depends upon the physicochemical properties of material. The planktonic bacterium moves 
towards the implant surface due to the effect of physical forces such as Van der Waals forces [153]. 
When the bacterium reaches a distance of 1 nm to the surface it adheres to the surface by ionic, 
hydrogen or covalent bonding [149]. After initial attachment, adhesion proteins on the bacterial 
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fimbriae support the bacterial adherence on the biomaterial [150]. Studies have shown that some 
specific proteins of bacteria also mediate their adherence to the surface; for instance, autolysins are the 
adhesion proteins that bind to the surface by hydrophobic or ionic interactions [154, 155]. The initial 
attachment or adhesion of the microbes to the surface of biomaterials is not sufficient for accumulation 
of bacteria on biomaterial surface. Subsequent to the initial attachment, bacteria change their 
phenotype and start secreting extracellular polymeric substances (EPS) that promote cell to cell 
aggregation process and forms microcolonies [149, 156]. Microcolonies are the basic units of a mature 
biofilm and upon encountering appropriate environmental conditions bacterial cells proliferate in the 
EPS matrix. Extracellular matrix includes the polysaccharides, proteins, nucleic acids and lipids that 
promotes the cell to cell binding, provides mechanical stability and protects bacteria from dehydration 
and antimicrobial agents [157, 158]. Role of extracellular DNA in the biofilm formation was 
investigated for Bacillus cereus, S. aureus and L. monocytogenes [159-161]. Under adverse 
conditions, bacterial cells sense the environmental changes and communicate with each other to 
regulate the gene expression in accordance to maintain the existence of the entire community; such 
communication system is referred as Quorum sensing [162, 163]. This cell to cell signaling is cell 
density dependent as only bacteria in mature biofilm are able to perform the quorum sensing [164]. 
Several functions can be regulated through communication system such as release of virulence factors 
to increase attachment to the host cells, motility, secretion of defensive factors to fight against the host 
cells, DNA exchange and formation of three dimensional structures [163, 165, 166]. When mature 
biofilm structure reaches its maximum size, cells from the periphery detach due to nutrient depletion 
and migrate to a new potential site for biofilm formation [163]. The dissemination process also 
involves the movement of bacteria from the highly populated area to the periphery due to lack of 
nutrients. These cells have the ability to relocate and restart the biofilm formation processes [167].  
 
Figure 4 : Overview of the phases of bacterial biofilm formation on an implant surface [168]. 
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Bacterial infection not only leads to the loss of functionality of the implant but also damages 
surrounding tissue. These infections are mostly resistant to conventional antibiotics because bacteria 
propagate in self-produced matrix, which cannot be easily penetrated using conventional antibiotic 
therapy. The solution to problem is revision of implant surgery but risk of relapse of infection is high. 
For example, in primary replacements of hip and knee, the frequency of peri-prosthetic infection is 
between 1.5-2.5% and this rises to 5-40% after revision surgery [169]. Another example is penile 
prosthesis in which primary incidence is 2-5% but in revision patients it increases to 10% [170].  
2.5.2 Preventing biofilm infections 
 
Medical implants such as urinary catheters, vascular grafts, prosthetic joints, pacemakers, endotracheal 
tubes, breast implants and contact lens are prone to infection [171]. Biofilm formation on these 
implants imposes a serious concern to health. The hazardous consequences of biofilms on medical 
implants include tissue destruction, systemic infection and loss of implant functionality eventually 
leading to serious illness of patients. These infections are not only resistant to immune defense 
mechanisms but also to conventional antibiotic therapy. The only way is to prevent biofilm formation 
by controlling the behavior of bacteria and medical devices, for which numerous novel strategies are 
being followed: 1. Disabling quorum sensing by using biomolecules [172-174] 2. Biomaterials coated 
with nanoparticles loaded with antimicrobial agents 3. Immunotherapy includes blocking of receptors, 
responsible for bacterial cell adhesion to the surface or inhibiting the intercellular adhesion 4.  
Disrupting the extracellular polymeric matrices by using matrix targeting enzymes such as DNaseI or 
Proteinase K  [175]. Taken together, the bactericidal coatings on implants or coatings preventing 
bacterial adhesion to the surface appears to be the most promising strategy because it provides the 
local and slow release of antimicrobial agents that can prevent infection for an extended period. There 
are several anti-biofilm agents disrupting quorum sensing and matrix of the biofilms but their 
therapeutic efficacy is still a question. Besides, these agents are also immunogenic or allergic in some 
cases. 
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3. Aims 
 
Existing implant materials are not optimal materials because they are taken over from technical 
developments. There is a great need for implant materials designed for specific applications. Novel 
implant materials or coatings on standard materials need to be tested in vivo before introducing into 
clinics. So far, there are no methods that allow quantification of inflammatory potential of different 
implant materials in vivo. There are known implant materials of varying inflammatory potential that 
are clinically used. Glass and titanium implants are non-inflammatory but degradable polymers have 
different effect according to histology results [176]. Moreover, wear particulates of hip or knee 
implant materials cause inflammation [177]. To this end, there is a need of sensitive, accurate and 
reliable animal model to evaluate inflammatory potential of different implant materials. Therefore the 
aim of this study was: 
 
1. To characterize the inflammatory potential of various implant materials of different size and 
textures. 
2. Additionally, to establish a system that enables to continuously monitor implant-related 
inflammation  
3. To distinguish inflammatory potential of several implants in one mouse that will improve 
comparability between materials by eliminating animal to animal variability and will reduce 
animal usage. 
4. To differentiate inflammation due to injury, implant and infections  
5. To compare and evaluate sensitivity and reliability of different detection strategies. 
6. To establish a sensitive detection system to monitor bacterial infections that respond solely to 
infections and not to material induced inflammation or injury related surgery. 
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4. Outline of the study 
 
To distinguish inflammatory potential of implant materials, several approaches were used. To this end, 
the study is divided into three major parts in which the initial strategy was to target inflammatory 
reactive products by fluorescent imaging. The second approach was to visualize immune cells of 
inflammation by bioluminescent imaging. Finally, to detect implant infections a new compound has 
been synthesized which was tested in vivo in this study. 
 
4.1 Visualizing reactive inflammatory molecules by fluorescent imaging 
 
Reactive oxygen species generated by PMNs were monitored using hydrocyanines, a chemical sensor 
which when oxidized converts to fluorescent cyanines. Cyanines can be visualized by in vivo imaging 
after excitation in the near infra-red [45]. Second strategy is to image inflammatory proteases like 
cathepsins produced by PMNs and macrophages. A commercially available protease activated 
fluorophore can be used that is hydrolyzed in the presence of cathepsins [178]. The third approach 
involves the visualization of autotaxin activity. Autotaxin is an inflammatory enzyme that produces a 
lipid signaling molecule, eventually stimulating cell proliferation, migration and survival [179]. For 
imaging, a fluorophore linked to the quencher by the autotaxin sensitive substrate can be used. 
Autotaxin separates the quencher from the fluorophore that can then be visualized in the in vivo 
imaging system (Fig. 5).  
  
 
Figure 5:Inflammatory products imaged in the study : Following the implantation, proteins adsorb on the 
implant surfaces (A), PMNs from the blood vessels reach the site of implantation (B) and upon activation release 
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reactive oxygen species (ROS), proteases , lipases and IFN-β (in case of bacterial infection). The immune 
response is amplified by further recruitment of the immune cells (C).  (Picture was modified from [70]) 
 
4.2 Imaging inflammation using immune cells 
 
To detect implant induced inflammation in real time, inflammatory cells were isolated from the bone 
marrow of mice with substantial constitutive expression of luciferase under the transcriptional control 
of Mx-2 gene promoter [180]. Mx-2 promoter responds to type 1 interferons during bacterial infection 
in the host [181-183]. These bone marrow derived immune cells were adoptively transferred to the 
implanted mouse model. Different cell types like neutrophils, monocytes or total bone marrow cells 
were used to visualize and quantify inflammation (Fig. 6).  The biocompatibility of several implant 
materials of different size and texture was tested such as polymer poly lactic – co – glycolic acid 
(PLGA), titanium and magnesium discs and microspheres of different polymers.  
 
 
 
Figure 6: Flow scheme for monitoring inflammatory response to implant materials: Bone marrow cells 
were isolated from transgenic donor having substantial luciferase expression under the influence of Mx-2 
promoter. Neutrophil and monocyte representing cells were purified and adoptively transferred in the implanted 
mouse model and luciferase reporter expression was exploited to visualize the cells at the site of implantation. 
 
 
 
OUTLINE OF THE STUDY 
 
23 
 
4.3 Visualizing infection related cytokine and bacteria 
 
The incidence of implant related infection is higher in the early stages of implantation. Immune cells 
activated by the bacterial infection secrete cell signaling proteins like Interferon-β [184, 185]. 
Bacterial infections can be visualized using transgenic mice in which one allele of IFN-β gene is 
deleted by luciferase reporter gene for imaging [186].  
 
Alternatively, bacterial infection can be monitored by labelling bacteria in vivo. For this, bacterial iron 
acquisition system was used to label the bacteria. An agent based on 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid amide (DOTAM) derivatives comprising siderophores was synthesized (Fig. 
7). Siderophores are iron chelators that are synthesized by bacteria and exported in the extracellular 
environment to capture iron under nutrient limiting conditions. Here in this study, IFN-β reporter mice 
were used to visualize the immune response to bacteria (Pseudomonas aeruginosa) by bioluminescent 
imaging and fluorescence of the compound was visualized by the linked near infra-red Cy5.5 
fluorophore in same mice.  
 
 
Figure 7: Chemical structure of DOTAM-Cy5.5: Red circle represent near infra-red fluorophore Cy5.5 and 
circles in green represent siderophore catecholates. The middle ring is DOTA with amide groups to which 
siderophores are linked (chemical structure drawn and kindly given by Dr. Haiyu Hu) 
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5. Materials and Methods 
 
5.1 Materials 
 
Table 3 : List of equipments used 
 
Equipment Manufacturer Model 
Autoclave Belimed Dampf Sterilisator  
 
6-6-6 HS1,FD  
 
Biological stirrer Techne MCS-104S 
Cell counter Beckman Coulter Z2-AF263 
Cell separator MACS Miltenyi 
 
Centrifuges Heraeus 
Sorvall 
Multifuge X3 FR 
RC 5B Plus 
CO2 incubators Labotect C200 
Confocal microscope Zeiss LSM 510 Meta 
Deionized water Milli Q 
 
Electric Shaver Aesculap 
 
Flow cytometer BD Biosciences FACS Calibur 
BD™ARIA cell sorter 
Freezer - 20°C:Liebherr  
- 80°C: Thermo Forma  
 
Fridge Liebherr 
 
Hot plate IKAMAG® RET 
 
In vivo imaging machine Xenogen IVIS system, Caliper  
 
IVIS 200 
Light microscopes Nikon 
Olympus 
TMS 
CKX41 
Mini centrifuge Heraeus Christ Minifuge GL 
Biofuge fresco 
 
Micropipettes Gilson 
 
Nitrogen tank HarscoK Series 
 
pH meter Beckmann M340 
Photometer Nanodrop ND-1000 
Pipettor Pipetboy IBS Integra Bisciences 
 
Plate reader Tristar 2 Berthold technologies 
 
Precision weighing scale Sartorius 
 
Rotary shaker Certomat ® 
 
Spectrophotometer Eppendorf / Biophotometer 
 
Sterile work benches Baker/ BDK/ Heraeus SG 400 E / HSP 18 
Thermomixer Eppendorf 5437 
Vortex Scientific Industries Vortex- Genie 2 
Water bath GFL 
 
 
Table 4 : List of consumables 
 
Articles Company 
Cell culture plates (96 well) Nunc, Corning 
Cell strainer (100 µm) Nylon BD Falcon 
Falcon tubes (15, 50 ml) Greiner BioOne 
Flow cytometry tubes Sarstedt 
Injections (1 ml) Omnican ® F 
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Needles 26 G Sterican  
Pipette tips Star lab 
Polyglactin filaments Number 6-0 Ethicon 
Surgical kit Fine Science tools 
 
Table 5 : List of reagents 
 
Reagents Company Catalogue code 
Acetic acid Sigma 
 
Acetone Sigma 
 
Agarose Biozym 840004 
Formaldehyde solution Roth P087.3 
Hematoxylin-solution Sigma-Aldrich HHS16-500ML 
Interferon -β Cell culture supernatant of 
BHK-21 cells 
 
Isofluran Allbrecht GmbH A29951,0025 
Indocyanine green Sigma I2633 
Ketamine-xylazine Animal facility- HZI 
 
Luciferin  Synchem BC219 
Luciferase firefly juice P.J.K GmbH 102511 
Methanol J.T. Baker® 
 
Mouse GM-CSF recombinant 
protein 
ebiosciences 14-8331-62 
Sodium borohydride Sigma 
 
 
Table 6 : List of kits and fluorophores used 
 
Kits / Fluorophore Company Catalogue code 
ATX Red fluorophore Echelon Biosciences L2010 
BD cytofix/cytoperm kit BD Biosciences 554714 
Live dead viability cytotoxicity 
kit 
Molecular Probes L-3224 
Monocyte isolation kit mouse MACS Militenyi 130 – 100 – 629 
Neutrophil isolation kit mouse MACS Militenyi 130-097-658 
Prosense 680 Perkin Elmers P/N NEV10724 
   
 
Table 7: List of softwares used in the study 
 
Software Manufacturer 
Adobe design standard CS5 Adobe Systems Inc. 
Axio vision 4.9 Zeiss 
FlowJo 10  Tree Star 
GraphPad prism  
ImageJ rsbweb.nih.gov/ij/ 
Living image software version 4.3.1 Caliper life sciences 
Microsoft office 2007/2008 Microsoft Incorporation 
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5.2 Methods 
5.2.1 Sterilization 
 
Glassware was sterilized at 180°C for 4 hours. The surgical kit and plastic materials such as eppendorf 
tubes, pipette tips and solutions for cell culture were autoclaved at 121°C for 25 minutes. Temperature 
sensitive solutions were filtered through 0.22 µm size filter. 
5.2.2 Cell culture 
 
Cell culture work was carried out in a sterile workbench (Herasafe, Heraeus). The working surface 
was disinfected with 70% ethanol before and after use. In addition, disposable consumables or 
autoclaved or sterile-filtered solutions or media were used. Before starting work, all solutions and 
media were preheated in a 37°C water bath.  
 
Roswell Park Memorial Institute medium, RPMI powder 
 
100 ml HEPES (1 M), 1.68 g/l NaHCO3, pH 7-7.4, add H20 10 l 
 
100 x Pen / Strep  
 
6.06 mg / ml ampicillin (10,000U/ml), 10 mg/l streptomycin, pH 7.4, stored at -20°C 
 
100 x Glutamine  
 
29.23 mg/ml glutamine, sterile filtered, stored at -20°C 
 
Phosphate buffer saline (PBS)  
 
140 mM NaCl, 27 mM KCl, 7.2 mM Na2HPO4, 14.7 mM KH2PO4, pH 6.8-7.0 
 
TEP (trypsin EDTA)  
 
 6 mM EDTA, 0.1% trypsin (Gibco) in PBS 
 
ACK lysis buffer 
 
150 mM NH4Cl, 10 mM KHCO3, 0.1 µM EDTA, pH 7.2-7.4 
 
5.2.3 Bacterial culture 
 
Staphylococcus aureus (wild type) and Pseudomonas aeruginosa (PA01) wild type were kindly given 
by Dr. Siegfried Weiss (Molecular Immunology, HZI) and Dr. Susanne Haussler (Head of molecular 
bacteriology department, HZI) and grown in Lysogeny Broth medium. 
 
LB-Medium (Bacterial growth) 
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10 g/l Bacto Trypton, 5 g/l Yeast extract, 10 g/l NaCl 
 
LB Agarose plates 
 
500 ml LB, 7.5 g Agarose 
5.2.4 Preparation of hydrocyanine 
 
2 mg of indocyanine green was dissolved in 4 ml of methanol. 3 mg of sodium borohydride was added 
to carry out reduction reaction. The solution was stirred continuously for 5 minutes in absence of 
oxygen. Solvent was evaporated in the presence of vacuum using rotary evaporators. The dried 
powder was stored at -20°C overnight. Before injection, the reduced hydrocyanine powder was 
dissolved in 2 ml of deionized water making up the final concentration to 1 mg/ml [45].  
5.2.5 Heat inactivation of Staphylococcus aureus 
 
Heat inactivated Staphylococcus aureus suspensions were prepared by streaking the bacteria on a 
lysogeny broth medium (LB) agarose plate and incubated over night at 37°C. Single colonies were 
picked with a sterile needle and used to inoculate a liquid LB culture that was incubated on a rotary 
shaker at 180 rpm at 37°C. When the density of the culture reached an OD600 of 0.2, 1 ml of the 
bacterial culture was centrifuged at maximum speed in a centrifuge for 5 minutes at room temperature. 
The supernatant was discarded and the pellet was suspended in 1 ml of phosphate buffered saline 
(PBS), pH 7.0. For inactivation, the bacteria were heated to 75°C for 15 minutes and then stored on ice 
until use. 
5.2.6 Implant preparation 
 
Beads were implanted with and without heat inactivated S.aureus. Poly-(lactic-co-glycolic acid) was 
coated on plain titanium discs by dissolving 50 mg of PLGA powder in 1 ml of acetone and small 
volumes ~ 10 µl of the dissolved PLGA was added drop-wise on a titanium disc kept on hot plate, set 
at temperature of 60°C until the volume of 1 ml was finished. Coated discs were dried at room 
temperature for overnight. Injectable chitosan suspensions were prepared by dissolving 50 mg of 
chitosan in 50 ml of 0.1% acetic acid. 
 
Table 8: List of implants used in the study 
 
Implant type Dimensions Company 
Chitosan from shrimp shells  Sigma 
Magnesium discs 5 mm diameter - 2 mm 
thickness 
Institute of material science, 
Leibniz Universität, Hannover 
Titanium discs 7 mm diameter - 1 mm 
thickness 
TU Braunschweig, Germany 
PLGA powder  Sigma Aldrich 
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PLGA microspheres 1 µm Phosphorex, USA 
Porous glass beads Round – 4 mm , Pore size- 60 
µm 
VitraPOR 
Polystyrene microspheres 1 µm Phosphorex, USA 
Poly-L-lactic acid beads 5 mm diameter GoodFellow, England 
   
 
5.2.7 Subcutaneous implantations in mice 
 
C57BL/6 mice were housed under specific pathogen free conditions. Anesthesia was induced by the 
intraperitoneal injection of ketamine (10 mg/kg) and xylazine (4 mg/kg) in PBS in mice. The dorsal 
side of the mice was shaved using an electric shaver and wiped with tissue dipped in 70% ethanol to 
remove remains of hair after shaving. A small incision of 1 cm was made in the dorsal skin using 
micro dissecting scissors. A pouch under the skin was created for implants. Incisions were closed by 
interrupted suturing using polyglactin filaments Number 6-0 (Ethicon, Germany). For mock 
implantations involved the entire surgical procedure without any inserted implant material. For 
injectable biomaterials, 50 µl of suspension was injected using 1 ml syringe on the shaved back of the 
mice. All animal experiments were done in accordance with the regulations and with the approval 
from the local authorities Lower Saxony State Office for Consumer Protection and Food Safety 
(LAVES), permission number 33.42502/07-10.5. 
 
Table 9 : List of mice used in the study 
 
Genotype Background Reference 
Wild type C57BL/6 Harlan Laboratories 
Wild type Balb/c Harlan Laboratories 
IFN-β+/∆β-luc Balb/c - albino C57BL/6 [186] 
Mx-2 Luc C57BL/6 [180] 
 
5.2.8 In vivo imaging of the oxidation potential using hydrocyanines 
 
After anesthesia 30 µg of hydrocyanine solution was injected subcutaneously at the site of 
implantation. After 30 minutes, fluorescent imaging was done in the near infrared spectrum using an 
in vivo imaging system (IVIS200). The excitation wavelength of hydrocyanines was 750 nm and the 
emission wavelength was 840 nm. Acquired images were corrected for the background using image 
math tool of living image software. In order to correct for the background, a region of interest was 
selected from a mouse without implants after addition of the fluorophore. The background value was 
calculated and automatically subtracted from the images by the software. 
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5.2.9 Monitoring inflammatory protease activity  
 
The protease activity dependent fluorescent sensor, Prosense 680 was used according to the 
manufacturer's recommendations. A dose of 2 nmol was injected intravenously into the mouse tail. 
Fluorescent imaging of the tissue with implants was done after a period of 30 minutes with an 
excitation and emission wavelength of 680 and 700 nm, respectively, using in vivo imaging system 
(IVIS 200). Similarly, the background of fluorescent images was subtracted using image math tool of 
living image software as described above. 
5.2.10 Visualization of cell growth signaling 
 
Lipase activity in the mouse tissue was monitored using ATX Red. 10 µg of ATX Red fluorophore 
was injected intravenously into the mouse tail. Whole animal imaging was done in the near infrared 
spectrum at an excitation and emission wavelength of 775 and 800 nm, respectively, 30 minutes after 
injection of ATX Red. Images were processed in the same way as explained above. 
5.2.11 Isolation of bone marrow cells from Mx-2 luc mice 
 
C57BL/6 mice that ubiquitously expressed luciferase from a Mx-2 luc construct were used for 
isolating the cells from the bone marrow [180]. Mice were euthanized by asphyxiation using CO2 in a 
chamber. Hind legs (femur and tibia) were removed and were cleaned from adhering tissues. These 
bones were kept in a petri plate filled with ice cold RPMI medium supplemented with 1% 
Penicillin/Streptomycin and 1% Glutamine. The bones were soaked in 70% ethanol for 1 minute and 
then transferred to fresh ice-cold RPMI media with supplements. Using veterinary scissors, joints of 
the bones were cut off. Bone marrow was flushed using a 26G syringe with filled ice cold RPMI 
medium and collected in a 50 ml falcon tube. The collected bone marrow was centrifuged at 1500 rpm 
for 5 minutes. The supernatant was discarded and the pellet was suspended in erythrocyte lysis buffer; 
ACK lysis buffer (1ml per mouse) followed by an incubation at room temperature for 1.5 minutes to 
remove erythrocytes. 10 ml of RPMI medium was added to neutralize the ACK lysis buffer and was 
centrifuged again at 1500 rpm for 5 minutes. The supernatant was discarded and cells were suspended 
in 10 ml of fresh RPMI media. Cells were filtered through 100 µm mesh and were counted using an 
automated cell counter.  
5.2.12 Purification of cell populations from isolated bone marrow cells 
 
Neutrophils and monocytes were purified from bone marrow cells by MACS (Magnetic Activated Cell 
Sorting) using Neutrophil isolation kit mouse and Monocyte isolation kit mouse (Miltenyi Biotech, 
Germany) respectively using a QuadroMACS™ magnetic separator. After isolation, cells were  treated 
with Fc blocking antibody for 20 minutes and then stained using anti-mouse Ly6G and anti-mouse 
Ly6C in FACS buffer (PBS + 2% fetal calf serum (FCS, Biovest, Germany)) for 30 minutes. Stained 
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cells were washed twice using PBS and were fixed following instructions of BD cytofix/cytoperm™ 
kit (BD Biosciences, Germany). Purified cell suspensions were acquired using BD LSR II flow 
cytometer (BD Biosciences, Germany) and analyzed using FlowJo software (TreeStar, Germany).  
5.2.13 Monitoring luminescence per cell 
 
Isolated neutrophils, monocytes and total bone marrow cells were cultured in 96 well plates in RPMI 
medium supplemented with 10% heat inactivated FCS, 1% Penicillin/Streptomycin, 1% Glutamine 
and mouse GM-CSF recombinant protein at concentration 5 ng/µl. The cell number of neutrophils, 
monocytes and total bone marrow cells per well was 103. 5 µl of heat inactivated S.aureus in PBS 
was added to the culture and as control 5 µl of PBS without bacteria was added to individual wells. 
To measure the luminescence of the cells, cultured neutrophils, monocytes and total bone marrow 
cells in 96 well plates were centrifuged at 1500 rpm for 5 minutes to settle down the suspended 
cells. The supernatant was carefully removed and discarded and 100 µl of luciferase firefly juice 
was added to the pellet and mixed. The luminosity was read in plate reader (Tristar2, Berthold 
Technologies). To determine the cell number, cells were stained using 2 µΜ of Calcein AM (Life 
Science Technologies, Germany) in PBS added to centrifuged pellet of cells (as described above) 
and kept at 37°C for 30 minutes. Cells were washed gently using 100 µl of pre-warmed PBS and re-
suspended in 100 µl of PBS. The relative fluorescence was measured in a plate reader at excitation 
and emission wavelength of 485nm and 535 nm. 
5.2.14 Adoptive transfer of cells and imaging 
 
Immediately after implantation, (~ 1 million) luciferase labelled cells were suspended in 150 µl of PBS 
and adoptively transferred through tail vein of C57BL/6 mice carrying implants. For in vivo 
visualization of the transferred cells, 150 µl of (30 mg/ml) luciferin was injected intraperitoneally. 
After 15 minutes, luminescent imaging was performed using an in vivo imaging system. Data were 
analyzed by Living image software® 4.3.1. To monitor the effect of type I interferon, in vivo imaging 
was performed of IFN-luciferase expressing mice before and after local injection of 1000 units of 
Interferon-β (IFN-β). Mouse IFN-β was recombinantly produced in stably expressing BHK-21 cells 
and was harvested from cell culture supernatant.   
5.2.15 Histology 
 
Mice were subcutaneously injected with 50 µl of PLGA and polystyrene microspheres of 1 µm in size 
and 50 µl of PBS. Mice were adoptively transferred with total bone marrow cells isolated from 
luciferase expressing mice and were sacrificed at day 2, day 5 and day 8. Tissue sections with local 
injection of microspheres and PBS were excised and transferred to tissue embedding cassettes. These 
tissue sections were fixed in 4% formaldehyde solution for not more than 48 hours and were then 
transferred to 70% ethanol solution. Histological slides of approx. 3 µm thickness were prepared from 
MATERIALS & METHODS 
 
31 
 
formalin fixed, paraffin embedded tissue. The sections were stained with Hematoxylin/Eosin (H&E) 
staining according to standard laboratory procedures. After heat mediated antigen retrieval, 
immunohistochemistry was done. Tissue sections were treated with anti-Myeloperoxidase and anti-
IBA-1. Anti-myeloperoxidase stains myeloperoxidase protein expressed by neutrophils. Anti-IBA-1 is 
ionized calcium binding adaptor molecule-1 expressed specifically by macrophages.  
 
Table 10 : List of antibodies 
 
Antibody Company Dilution 
Anti-mouse Ly6G – V450 BD Biosciences 1:400 
Anti-mouse Ly6C - APC BD Biosciences 1:200 
Fc blocking antibody Group of Molecular Immunology - 
HZI 
1:500 
Anti-myeloperoxidase (rabbit 
polyclonal) 
Thermo Scientific 1:200 
Anti-IBA-1 (rabbit polyclonal) Synaptic systems 1:800 
   
 
5.2.16 Imaging interferon-β induction in transgenic reporter mice 
 
Transgenic female BALB/c mice with a luciferase gene replacing IFN-β coding sequence on one allele 
were used for non-invasive in vivo imaging of the IFN-β induction [186]. 150 µl of (30 mg/ml) 
luciferin was injected intraperitoneally. After 15 minutes, luminescent imaging was performed using 
an in vivo imaging system (IVIS 200).  
5.2.17 Imaging bacterial infection using a siderophore containing compound 
 
Wild type P.aeruginosa (PA01) were streaked on LB agarose plates and incubated at 37°C overnight. 
Single colonies were picked and inoculated in LB media. Inoculated cultures were incubated on 
shakers at 180 rpm at 37°C until the optical density of the culture reached OD600 0.1. IFN-β reporter 
mice were used to visualize the immune response to infection. The dorsal side of the mice was shaved 
and 5 µl of bacterial culture was injected subcutaneously. Siderophore containing compounds were 
synthesized in the Helmholtz Centre for Infection Research, Braunschweig by Dr. Haiyu Hu. After 
infection, the Cy5.5 conjugated siderophore compound (20 µg/kg of mouse body weight) and as a 
control Cy5.5 without siderophore were injected intravenously in mice through the tail vein. 
Fluorescent imaging was performed at excitation and emission wavelengths of 675 and 694 nm, 
respectively. For visualizing the immune response, 150 µl of (30 mg/kg) luciferin injected in the same 
mice after 5 hours of infection and bioluminescent imaging was performed. Mice were sacrificed and 
organs such as liver, spleen, kidneys, intestine and heart were extracted and fluorescent imaging was 
done at excitation and emission wavelengths of 675 and 694 nm, respectively. Fluorescent images 
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were processed by subtracting the autofluorescence of tissue using image math tool of Living image 
software. 
5.2.18 Neutrophil culture  
 
Neutrophil representing cells were isolated from bone marrow of luciferase expressing mice using 
MACS isolation kit and were sorted again using BD FACSAria™ III to separate side population of 
Ly6Chi monocytes and get pure neutrophils (Ly6G+/Ly6Cint). 105 purified neutrophil cells were 
cultured in RPMI media with 10% heat inactivated FCS, 1% Penicillin/Streptomycin, 1% Glutamine 
and in presence and absence of growth factor mouse GM-CSF recombinant protein at concentration 
of 5 ng/µl in 96 well plates.  Half of the media with or without GM-CSF was replaced every second 
day of culture. Luminosity from the cells was measured using plate reader. For live dead assays, 
pure neutrophils and contaminating Ly6Chi monocytes were cultured at cell density of 2×103 cells in 
each well of 96 well plates with or without 5 ng/µl of GM-CSF. Live dead staining was performed 
by following the instructions of the kit (Live dead viability cytotoxicity, Molecular Probes). Images 
were acquired using fluorescence confocal microscopy. 
5.2.19 Phenotype of sorted and purified neutrophils in presence of GM-CSF 
 
Purified neutrophil cell culture after sorting was analyzed by FACS as follows. Cells were incubated 
in 50 µl of trypsin for 3 minutes and then 100 µl of RPMI medium was added to neutralize trypsin. 
Cells were then transferred to fresh 96 well plates and centrifuged at 1500 rpm for 5 minutes. The 
supernatant was discarded and the cell pellet was suspended in Fc blocking antibody for 15 minutes. 
The plate was centrifuged and the supernatants were discarded. Cell pellets were suspended in a mix 
of Ly6G and Ly6C antibodies as described above and incubated for 30 minutes at 4°C. Cells were 
washed twice using PBS and then fixed using BD cytofix/cytoperm™ kit (BD Biosciences). Fixed 
cells were acquired using BD LSR II flow cytometer and analyzed using BD FACSDIVA software as 
described above.  
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6. Results  
 
6.1  Fluorescent inflammation reporter molecules 
6.1.1 Monitoring reactive oxygen species produced in response to inflammatory 
implants using a chemical sensor 
 
To visualize the inflammatory potential of implants over the time, biocompatible and immune 
stimulatory materials were implanted subcutaneously in mice. During inflammatory conditions, 
neutrophils and macrophages are known to produce reactive oxygen products which can be detected 
after subcutaneous administration of hydrocyanines [45, 70]. Cyanine was reduced to hydrocyanine. 
This reduced dye becomes fluorescent after an oxidation reaction with oxygen radicals. To investigate 
this detection method, highly inflammatory porous glass beads loaded with heat-inactivated bacteria 
were used to stimulate the immune response. In vivo imaging revealed increases in fluorescence 
intensity during first two days (Fig. 8 A). The site with the bacteria appeared brighter fluorescent when 
compared to bare glass implants. These results showed that oxidation sensitive dyes could be used to 
differentiate inflammatory and biocompatible implants. However, the response to a sterile implant and 
surgical injury in absence of implants showed similar fluorescence intensities and could not be 
differentiated by this method (Fig. 8 B). The difference observed in the relative fluorescence 
intensities at the site of sterile and bacterial coated implants was around 1.5 fold (Fig. 8 B). This 
showed the low sensitivity of the detection system. Moreover, after systemic administration of 
hydrocyanine fluorescence was not detected at the site of inflammation or implantation. Instead, the 
signal was detected from the organs of the mouse, locations corresponding to liver and lungs (Fig. 8 
C).  
 
Figure 8: Enhanced oxidizing potential in response to inflammatory implants visualized by a fluorescent 
probe: Biocompatible glass implants and glass implants coated with inflammation-inducing heat inactivated S. 
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aureus were subcutaneously implanted into Balb/c mice. Hydrocyanine solutions were injected at the site of 
implantation as oxidation-sensitive dye precursor molecules. Fluorescence intensity was determined at 0 h, 6 h 
and 48 h after dye injection (A). The fluorescence efficiency was quantified at 24 hours and normalized to initial 
time point (B). The following implants were used: 1. Glass bead coated with inactivated bacteria; 2. Glass bead 
implant; 3. Surgery without implant. Dashed circles represent the site of implantation. 
6.1.2 Visualization of inflammation specific proteases  
 
Immune cells recruited during inflammation secrete some enzymes such as proteases which is 
essential to allow migration of cells through the tissue. To observe if cathepsin protease activity could 
be used to distinguish inflammatory from non-inflammatory implants, different implant materials were 
subcutaneously implanted in mice. A commercially available cathepsin-activatable fluorophore was 
injected intravenously in mice and whole body imaging was performed. The results showed an overall 
increase in fluorescence intensity with time (Fig. 9 A). The fluorescence appeared to be delocalized 
and could not be assigned to individual implants. Furthermore, opaque implants quenched even the 
background fluorescence. This phenomenon could be used to precisely localize the position of the 
implants (Fig. 9 A; implant 3 at 6 hours and 48 hours). At 48 hours, the implant with bacteria showed 
a brighter fluorescence compared to the biocompatible glass implants (Fig. 9 A; 48 hours). The 
relative fluorescence associated with implants (Fig. 9 A; implant 1, 2 and 6 at 48 hours) was calculated 
and small differences between implants with and without bacteria were observed (Fig. 9 B). However, 
the signal intensities from the implant and injury alone were similar, indicating that only highly 
inflammatory bacterial products could be differentially recognized by this approach (Fig. 9 B). 
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Figure 9: Delocalized protease activity in response to pro-inflammatory implants over the time period: 
Fluorescent images were taken at 0 hr, 6 hrs and 48 hrs (A). Relative fluorescence intensity related to implant 1, 
2 and 6 was calculated at 48 hrs (B). The format of implantation was following- 1. Porous glass implant soaked 
in dead bacteria 2. Porous glass implants 3. Magnesium 4. Poly-L-lactic acid 5. Heat killed bacteria & 6. Surgery 
without implantation. Dashed circles represent the site of implantation. Fluorescence was quantified after 48 
hours and normalized to values of 0 hr to calculate relative fluorescence efficiency (B). 
6.1.3 Monitoring inflammatory cell growth signals 
 
Injury stimulates cell growth and tissue repair processes [114]. Cell growth, survival and migration 
can be stimulated by lipase signaling [187]. Autotaxin is an inflammation specific lipase that activates 
a lipid mediator essential for cell motility and growth signaling, it has been shown to be produced in 
lung inflammation [179, 187]. ATX Red is a near infra-red fluorescent precursor molecule and 
analogue of the substrate for autotaxin lipase. This enzyme substrate reaction generates a fluorescent 
product that can be detected by in vivo imaging. Various biocompatible and inflammatory implant 
materials were implanted in mice to evaluate this method. After implantation, mice were injected 
intravenously with ATX red (Fig. 10; 0 hour). To monitor the basal levels of autotaxin, one mouse 
without implants was included (Fig. 10). Enhanced signals were observed from the implants with 
bacteria as compared to biocompatible glass implant (Fig. 10; implant 2, 48 hours). A signal peak was 
obtained 48 hours after the dye injection at a site where there was no implant and which may 
correspond to the location of the spleen (Fig. 10, 48 hours, yellow spot on the left side of each animal). 
However, the autotaxin activity appeared to be delocalized and there was a high background signal, 
making it difficult to determine the response to individual implants. Quenching of the fluorescence 
signal was also observed at the site of opaque implants (Fig. 10; implant 4, 6 and 48 hours). 
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Figure 10: Imaging of increased but delocalized inflammatory cell proliferation signals: Mice were 
implanted with various inflammatory and non-inflammatory materials. ATX-red was applied and fluorescent 
images of the following time points: 0hr, 6hrs and 48hrs. The first two mice from the left were with implants and 
the third mouse is without implants and surgery. Implants were as follows: 1. Porous glass implant 2. Porous 
glass implant with dead bacteria 3. Poly-L-lactic acid 4. Magnesium 5. Mock and 6. Titanium. Dashed circles 
represent the site of implantation.  
 
6.2  Imaging implant induced inflammation using bioluminescent immune 
cells 
6.2.1 Purified luminescent labelled cells could be visualized and quantified after local 
injection in vivo 
 
To evaluate the inflammatory potential of implant materials, luciferase labelled immune cells were 
employed. These cells were isolated from mice with substantial ubiquitous luciferase expression under 
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the influence of Mx-2 promoter sequences. Neutrophils and monocytes were purified from the bone 
marrow of luciferase expressing mice and were analyzed using Ly6G and Ly6C surface markers 
which are known to differentiate neutrophils from monocytes [188-190]. Approximately 85% 
population was positive for both markers (Ly6G and Ly6C) representing neutrophil population and 
14% of the side population were Ly6G- and Ly6Chi (Ly6C high) monocytes (Fig. 11 A). Similarly, 
isolated monocytes were Ly6C positive cells (~ 91%) with minimal double positive cells (Fig. 11 B).  
 
To visualize the luminescence of cells in vivo, same number of total bone marrow cells and purified 
neutrophils and monocytes were locally injected in the mice with or without heat inactivated bacteria. 
Luminescence of neutrophils, monocytes and total bone marrow cells was detectable at 0 hour. The 
signals of total bone marrow cells, neutrophils and monocytes gradually increased and peaked on day 
1. Increase in luminosity of cells was irrespective of presence or absence of bacteria. Therefore, this 
temporal increase of luminescence might be due to cell proliferation (Fig. 11 C). The radiance from 
the monocytes in presence or absence of heat inactivated bacteria was higher than neutrophils or total 
bone marrow cells till day 2 (Fig. 11 D & E). Moreover, a 5-fold difference was observed in the 
luminosity of the monocytes in the presence versus absence of dead bacteria on day 2 reflecting the 
effect of bacterial extract on Mx-2 promoter dependent luciferase activity (Fig. 11 D & E). These 
results indicated that basal luminescence of monocytes was higher than neutrophils or total bone 
marrow cells. Moreover, the luminescence of monocytes was enhanced in presence of bacteria which 
could be due to induced promoter.  
 
 
 
Figure 11: Luminescence quantification from the locally injected inflammatory cells in vivo: Neutrophils 
(A) and monocytes (B) were purified from the bone marrow of luciferase expressing mice using MACS 
purification kit. Purified cell populations were stained for Ly6G and Ly6C surface marker and analyzed using 
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FACS (A & B). Heat inactivated bacterial suspension were subcutaneously injected in the mice. Then, an equal 
number (105 cells) of total bone marrow cells, neutrophils and monocytes were added locally at the site of 
bacterial infection in the mice and bioluminescent imaging was performed by injecting luciferin substrate (C). 
The numbers indicate: 1. Total bone marrow cells 2. Neutrophils 3. Monocytes (C). ‘+’ reflects the presence of 
heat inactivated S.aureus and ‘–’ indicates its absence (C). The average radiance values were calculated for bone 
marrow cells, neutrophils and monocytes in the absence and presence of heat inactivated bacteria (D and E).  
6.2.2 Luminescence of single cells 
 
To determine relation between luminescence and cell proliferation, an in vitro experiment was set up 
in which the neutrophils and monocytes were isolated from the total bone marrow cells of luciferase 
expressing mice and cultured with or without heat inactivated bacteria. The luminosity of the 
luciferase labelled immune cells was read using a plate reader and represented as relative 
luminescence units (RLU). To determine the cell viability and proliferation, cultured cells were stained 
with a cell permeant calcein stain and fluorescence of the dye was read as relative fluorescence units 
(RFU) in a plate reader. In this case, manual counting of cell number was difficult because the culture 
contained both adherent cells and cells in suspension. So, the cells can be lost during handling. 
Moreover, calcein is known to be more sensitive than trypan blue exclusion. The fluorescent dye 
stains live cells by reacting to intracellular esterases while dead cells lack active esterases. The 
background of the calcein is very low because it must interact with esterases of live cells to become 
fluorescent. Therefore, the fluorescence intensity is directly proportional to cell number.  
 
The total bone marrow cells showed similar luminescence intensity (RLU) when cultured with or 
without dead bacteria indicating minimum effect of bacterial components on Mx-2 promoter 
dependent luciferase expression (Fig. 12 A). However, the viability of cultured bone marrow cells was 
checked using a cell permeant fluorescent dye and a small increase in fluorescence intensity (RFU) of 
total bone marrow cells in presence or absence of dead bacteria was observed which could be due to 
increase in cell number (Fig. 12 A). Neutrophils cultured with or without dead bacteria showed almost 
identical changes in luminosity and fluorescence intensity when compared to total bone marrow cells 
(Fig. 12 A & B).  
 
In contrast, monocytes were found to be 4-fold higher luminescent than neutrophils and total bone 
marrow cells at 6 hours. However, the fluorescence intensity of the monocytes at the initial time point 
(6 hours) was comparable to neutrophils and total bone marrow cells which were in accordance with 
the equal number of cells in the inoculum. This showed that monocytes had higher basal luciferase 
expression than neutrophils and total bone marrow cells (Fig. 12 C). In addition, the differential 
promoter activity of monocytes could be seen after 24 hours where luminosity of monocytes was 
higher in presence than in absence of dead bacteria (Fig. 12 C; RLU). Moreover, the fluorescence 
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intensity of monocytes was increasing after 24 hours of culture that indicated rapid proliferation of 
monocytes (Fig. 12 C; RFU). Interestingly, on comparing fluorescence intensity of monocytes in 
presence versus absence of bacteria after 48 hours and 72 hours, it was observed that number of 
monocytes decreased in presence of dead bacteria. This could be due to apoptosis of monocytes after 
phagocytosis of bacterial components. Such process is known as phagocytosis induced cell death 
(PICD) [191] (Fig. 12 C; RFU). However, the luminosity of monocytes in presence of dead bacteria 
after 48 and 72 hours was comparable to the luminescence in absence of bacteria that could be due to 
induction of promoter by bacterial components (Fig. 12 C; RLU). 
 
These results suggested that monocytes were highly luminescent when compared to neutrophils or 
total bone marrow cells and the increase in cell number of monocytes in vitro was in agreement with 
in vivo studies (Fig. 12 C & 11 D). So far, we assumed that monocytes could be an optimal cell 
population for distinguishing inflammatory responses to implant materials due to observed higher 
basal luciferase activity than total bone marrow cells and neutrophils, differential promoter activity in 
presence of stimulus and rapid proliferation when compared to total bone marrow cells and 
neutrophils. 
 
 
 
Figure 12: Luminescence per cell in inflammatory or non-inflammatory conditions: Luminescent labelled 
total bone marrow cells (A), neutrophils (Ly6G+/Ly6Cint) (B) and monocytes (Ly6G-/Ly6Chi) (C) isolated from 
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bone marrow of luciferase expressing mice were cultured separately. Heat inactivated bacterial suspensions were 
added to the cell cultures. Luminosity was measured after adding luciferin to the cells and relative luminescence 
units (RLU) were calculated in a plate reader. For quantification of live cells, cells were stained using the 
fluorescent dye for live cells and the fluorescence (RFU) was measured in plate reader with excitation and 
emission filter of 485 nm and 535 nm, respectively. 
6.2.3 The ability of neutrophils to accumulate at the site of inflammation is rapidly lost 
 
There were two aims of this experiment, one was to find out the distribution of intravenously 
transferred cells in the mouse and second was to observe migration of cells in case of delayed or no 
inflammation. To achieve the goal, we needed a constant cell number throughout the experimental 
study. Therefore, neutrophils were used due to their non-dividing ability. Firstly, to determine 
distribution of intravenously injected cells, implants were inserted and neutrophils were adoptively 
transferred. Mice were sacrificed and bioluminescent imaging of organs was performed. After 6 hours 
of adoptive transfer, higher luminescence was observed in the spleen which was diminished at later 
time points indicating a probable role of spleen for homing of neutrophils (Fig. 13 A).  
 
Secondly, to visualize the inflammation specific cell migration, neutrophils were adoptively 
transferred in the mice and inflammation by implantation procedure was stimulated at later time points 
post adoptive transfer of cells (Fig. 13 B). The luminosity decreased gradually in the case of delayed 
implantations or injury. The average radiance from the inflammation site progressively decreased with 
the increased delay in inducing an inflammatory insult and no signal was observed in absence of 
inflammation on day 5 (Fig. 13 B). This indicated that the ability of neutrophils to reach to the site of 
inflammation was lost after 24 hours. Therefore, adoptive transfer of the cells and insertion of 
implants must be at the same time. Secondly, if there is no inflammation, transferred neutrophils 
disappeared from the circulation after 24 hours. There could be two possibilities, either neutrophils 
were undergoing apoptosis in absence of inflammation or cells were present but were unable to reach 
the inflammation site.  
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Figure 13 : One day time window for adoptively transferred neutrophils to migrate to the site of 
inflammation. Bioluminescent imaging of spleen, liver and kidney of the mouse with inflammation and 
adoptively transferred neutrophils (A). Mice were implanted 0, 6 hrs, 12 hrs and 24 hrs post adoptive transfer of 
purified neutrophils from bone marrow of luciferase expressing mice. Bioluminescent image at day 5 was 
produced and quantified. The implants are as follows: 1. Porous glass bead 2. Incision injury without implant. 
The dashed circle represents the site of implants (B). 
6.2.4 Effect of IFN-β on the luminescence of neutrophils 
 
Neutrophils are considered to be non-dividing cells; therefore the luminosity of cells could not depend 
upon the cell number. We needed a constant cell number to visualize signals only in response to the 
induced promoter. Interferon-β (IFN-β) is a potent inducer of Mx-2 promoter activity [180]. The 
recombinant Mx-2 promoter-luciferase construct has detectable activity even in the absence of 
interferon-β. To quantify the effect of IFN-β on Mx-2 promoter dependent luciferase expression 
neutrophils were isolated from the bone marrow of mice with expression of luciferase under the 
influence of Mx-2 promoter and were adoptively transferred in mice with implants. Interferon-β was 
locally injected on the top of implant and imaging was done before and after 6 hours of treatment each 
day (Fig. 14 A). The luminescence before and post IFN-β addition was found to be almost identical up 
to 6 days (Fig. 14 B). Local additions of IFN-β did not improve the luminescence of the neutrophils at 
the inflammation site suggesting the saturation of promoter activity due to endogenously produced 
IFN-β in response to sterile injury. Injury associated with implantation procedure involves necrotic 
cell death. These cell remnants can be internalized by macrophages and transferred to lysosomes. In 
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absence of DNase II alpha in lysosomes, DNA is not degraded and can stimulate the production of 
type I interferons through STING signaling [192]. Therefore, the basal promoter activity appeared to 
be very high with a minimal influence of IFN-β on the luminosity of neutrophils. 
 
 
Figure 14: Minor effects of local additions of IFN-β on the luminescence of adoptively transferred 
neutrophils: Neutrophils were isolated from the bone marrow of luciferase expressing mice and adoptively 
transferred into mice with porous glass bead implants. Imaging was performed before treatment and after 6 hrs 
post injection of IFN-β each day (A). The luminosity was quantified before and post 6 hours of subcutaneous 
application of IFN-β each day, starting from d0 (B). 
6.2.5 Sensitive detection of labelled bone marrow cells accumulated at the site of 
implantation and unexpected longevity of neutrophil population 
 
The aim of present work was to visualize labelled immune cells at the site of implantation after 
intravenous adoptive transfers. To this end, inflammatory and non-inflammatory materials were 
implanted and purified labelled total bone marrow cells, neutrophils and monocytes were adoptively 
transferred. Total bone marrow cells, neutrophils and monocytes could be detected at the site of 
inflammation 24 hours post adoptive transfer (Fig. 15 A, B & C). The brightness increased at the site 
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of inflammatory implant surface 3 days after adoptive transfer of total bone marrow cells and 
neutrophils (Fig. 15 A & B; d3). The signal intensity of total bone marrow cells and neutrophils 
reached their maximum on day 5 and then a gradual decrease was observed and eventually signal 
disappeared after 19 days (Fig. 15 A & B). However, neutrophils are short living cells with half-life of 
few hours in circulation but surprisingly; we observed their prolonged survival in tissue which was 
unexpected. For monocytes, the luminescence at site of implants remained constant after day 2 and the 
signal intensity was not different for implant with or without dead bacteria (Fig. 15 C). Although, 
luminosity of monocytes could be distinguished at the incision site between the two implants on day 2 
which might be due to inappropriate closure of wound (Fig. 15 C). The luminescence of monocytes 
disappeared after 9 days of adoptive transfer which is much earlier than total bone marrow cells and 
neutrophils (Fig. 15 C).  
 
Results from this experiment indicated that bioluminescent labelled immune cells were detectable at 
the inflammation site and signals were localized to the site of implants or injury. As a part of side 
finding, we also observed prolonged neutrophil survival in tissue which was unexpected due to their 
short half-life in circulation.  
 
 
 
Figure 15: Detectable and localized signals from labelled immune cells accumulated at the site of 
implantation: Mice were implanted with porous glass beads subcutaneously with or without heat inactivated 
bacteria. Dashed circles in red represent the site of implant with heat inactivated bacteria and black colored 
circles represent the site of sterile implant. The same number of total bone marrow cells (A), neutrophils (B) and 
monocytes (C), isolated from the bone marrow of luciferase expressing mice, were adoptively transferred in the 
mice with the implantations. Bioluminescent imaging was performed by injecting luciferin substrate in an IVIS 
200 imager. Black boxed mice indicate the control animals with transferred cells but without implantations. 
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6.2.6 Bioluminescent bone marrow cells could differentiate infected and sterile 
implants 
 
To identify optimal cell population for evaluation of inflammatory responses to implant materials, the 
luminescence of neutrophils, monocytes and total bone marrow cells accumulated at the site of 
inflammation was quantified and intensity was compared. Signals were localized because of which 
quantification was possible. On day 1 post adoptive transfer of labelled immune cells, total bone 
marrow cells, neutrophils and monocytes could be detected at the site of implantation but 
luminescence of cells were close to background (Fig. 16 A, B & C). Moreover, the luminosity of total 
bone marrow cells, neutrophils and monocytes increased at the site of implants after 2 days of 
adoptive transfer (Fig. 16 A, B & C). There were differences in the signal intensities from the site of 
infected implant and sterile implant in case of each cell type (Fig. 16 A, B & C). However, this 
difference was highest ~ 3.5 fold in mice transferred with total bone marrow cells on day 5 which 
becomes lesser at later time points (Fig. 16 A). This means that transferred total bone marrow cells 
showed clear difference between infected and sterile implants which was restricted to one time point. 
In contrast, infected implants could not be differentiated from sterile implants using neutrophils and 
monocytes due to small differences in signal intensity (Fig. 16 B & C). However, the luminescence of 
total bone marrow cells, neutrophils and monocytes recruited at the site of sterile implant appeared 
similar (Fig. 16 A, B & C).  
 
Results revealed that total bone marrow cells recruited at the inflammation site were able to 
distinguish the infected and sterile implant materials. Bioluminescent bone marrow cells were found to 
be optimal cells that can be used to screen the biocompatibility of different implant materials. This 
method fulfilled our all expectations. Signals were localized and clearly detectable. Moreover, the 
difference between inflammatory or non-inflammatory implant materials could be clearly observed. 
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Figure 16 : Differential signal intensities at the site of infected and sterile implants: Total bone marrow cells 
(A), neutrophils (B) and monocytes (C) isolated from luciferase expressing mice were adoptively transferred 
through tail vein to the mice (n=5) carrying implantations of glass beads with or without heat killed (HK) 
bacteria. Images were acquired using IVIS 200 and quantified to show the luminosity appearing at the site of 
implantations. 
6.2.7 Differential response to surgical injury and injection associated injury 
 
Injury due to surgery induces inflammation even in the absence of implants [114]. To evaluate the 
tissue reaction in response to injury, luciferase labelled total bone marrow cells were adoptively 
transferred to the mice with injury but without implants. As a control, PBS was subcutaneously 
injected without surgical wounds in mice and the radiance values were compared to the injury due to 
incision (Fig. 17). Signal intensity at the site of buffer injection was close to the basal values and 
larger relative difference was observed from injury (Fig. 17). This assay showed that implantation 
associated injury was a potent stimulant of inflammation and bone marrow cells were accumulated at 
the inflammation site. The luminosity at the site of surgical incision was similar when compared to 
sterile implants which indicated that signals from sterile implants were due to injury and not due to 
implant (Fig. 17 & 16 A).  
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Figure 17: Inflammatory insults induced luminescence signal from adoptively transferred cells: Total bone 
marrow cells were adoptively transferred in two groups of mice, one group was treated with surgical injury (n=4) 
and other group of mice was treated with subcutaneous saline buffer injections (n=4). Bioluminescent imaging 
was done and images were quantified using Living image software. 
6.2.8 Differentiating inflammatory potential of implant materials using bioluminescent 
immune cells 
 
To rank inflammatory potential of clinically established materials, several implant materials were 
tested. Implant of biodegradable polymer, poly-lactic-co-glycolic acid (PLGA) was chosen as an 
inflammatory material because of production of acidic degradation products that induces immune 
response [193]. Titanium (Ti) and magnesium (Mg) discs were used as biocompatible controls. 
Inflammatory and biocompatible implants were implanted in mice and luciferase labelled total bone 
marrow cells were adoptively transferred in mice with implants. Luminescence of total bone marrow 
cells was detectable at the site of implantation on day 1 (Fig. 18 A). Amongst the three biomaterials 
used for testing, luminescence at the site of implanted PLGA discs increased gradually with a peak on 
day 3, day 4 and day 5 (Fig. 18 A; implant 1). In contrast, the signals were comparatively weaker at 
the site of titanium and magnesium implants (Fig. 18 A; implant 2 & 3). After quantification, signals 
from PLGA implant were significantly higher when compared to titanium and magnesium implants 
after 3 days of adoptive transfer (Fig. 18 B). A weak signal was observed at the site of magnesium 
implants on day 4 which could be injury related (Fig. 18 A; implant 3). 
 
We observed localized inflammatory response to PLGA implants. Moreover, the signal was clearly 
detectable above background due to bioluminescent imaging. In addition, inflammatory materials were 
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clearly differentiated from known biocompatible implants. This indicated that the system was sensitive 
and could reliably distinguish inflammatory potential of implant materials.  
 
 
 
Figure 18: Ranking inflammatory potential of different biomaterials: PLGA material coated on titanium 
implant, plain titanium and magnesium implants were implanted in mice and luminescent bone marrow cells 
were transferred through tail vein. Bioluminescent images were produced using IVIS 200 (A) and quantified (B). 
The following implants were used: 1. PLGA coated titanium (7mm diameter and 0.1 mm thickness) 2. Titanium 
(Ti) (7mm diameter and 0.1 mm thickness) 3. Magnesium (Mg) (3mm diameter and 2 mm thickness). The 
dashed circles in red represent the site of implants. 
6.2.9 Separating material induced inflammation from injury 
 
Injury and material interactions both contribute to the resulting implant induced inflammation [70]. 
However, injections induce minimum tissue injury. Therefore, to separate the response to surgical 
insults from material induced inflammation, injectable biomaterials were used. Microspheres are the 
ideal injectable materials used for diagnostics or drug delivery purposes [194]. In this case, two types 
but similar sizes (1 µm) of microspheres were used, one of them was PLGA which is known to be 
biodegradable with the production of acidic by products and the other type was polystyrene, a non-
degradable polymer that has the property to stay in the recipient for longer times. Polystyrene and 
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PLGA micro particles have already been characterized as inflammatory in animal test models [45, 47, 
54]. Chitosan, one of the naturally occurring polysaccharides which have its application in wound 
dressing and drug delivery was another type of injectable material used [195, 196].  
 
All the materials were applied subcutaneously in mice and luciferases expressing total bone marrow 
cells were adoptively transferred. Transferred immune cells were detectable at the site of implants 2 
days after adoptive transfer (Fig. 19 A). Radiance of cells at the site of saline buffer injections was 
close to background which indicated minimum injury due to injection (Fig. 19 A; implant 2). Signals 
increased gradually in response to all implant materials (Fig. 19 A). The luminosity of cells recruited 
at the injection site of PLGA microspheres increased till day 5 and then disappeared which could be 
either due to resolution of material induced inflammation or resorption of the implant (Fig. 19 A; 
implant 3). Immune cells accumulated at site of chitosan injection showed saturated signals from day 3 
till day 8 which then decreased afterwards (Fig. 19 A & B; implant 1). Luminescence of cells at the 
site of polystyrene implants was increasing gradually and peaked on day 5 with a gradual decrease 
with time (Fig. 19 A; implant 2). However, luminescence at the site of polystyrene implants persisted 
for more than 13 days when compared to PLGA and chitosan implants which indicated chronicity of 
the inflammatory response due to its non-degradable behavior (Fig. 19 A; implant 2). On comparing 
signal intensities, signal from location of polystyrene was significantly higher than from chitosan and 
PLGA implants on day 5 and day 6 post adoptive transfers of cells (Fig. 19 B).  
 
This showed the uppermost inflammatory potential of polystyrene implants when compared to 
chitosan and PLGA implants as expected. Therefore, we were able to detect and quantify material 
induced inflammation by using injectable materials. The model could detect localized inflammation in 
response to materials and eventually could rank the inflammatory potential of implant materials. 
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Figure 19: Higher luminescence induced by polystyrene microspheres compared to degradable implants: 
To eliminate injury from the inflammation model, injectable biomaterials were employed. PLGA and 
polystyrene microspheres of 1 µm and chitosan in 0.1% acetic acid were injected locally in the mice as indicated. 
Luminescent bone marrow cells were adoptively transferred and the extent of inflammatory potential of each 
biomaterial was monitored using IVIS200 (A) and quantified using Living Image software (B) 1. Chitosan 2. 
PBS 3. PLGA microspheres (1µm) 4. Polystyrene microspheres (1µm). The dashed black circles represent the 
site of injection. 
6.2.10 Validation of the inflammatory reactions to the materials 
 
To confirm results from in vivo imaging of luminescent immune cells, histological examination was 
done. Mice were injected with PLGA microspheres, polystyrene microspheres and PBS 
subcutaneously and total bone marrow cells were transferred. Skin sections were excised after 
sacrificing the mice. The mouse skin tissue sections were evaluated using hematoxylin and eosin, anti-
IBA-1 and anti-myeloperoxidase. Hematoxylin and eosin stains nucleus and cytoplasm of the cells, 
thereby representing cells infiltrated in the tissue. On the other hand, IBA-1 is calcium binding 
protein-1 that is expressed specifically in macrophages [197]. We also checked myeloperoxidase 
activity in response to implants. Myeloperoxidase is an enzyme which is most abundantly expressed in 
neutrophil azurophilic granules.  
 
Saline buffer treated tissue did not reveal infiltration of inflammatory cells. However, the brown 
staining in muscular layer and epidermis of PBS treated tissue appears to be background associated 
with anti-IBA-1 and anti-myeloperoxidase staining (Fig. 20 A). The implantation of PLGA and 
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polystyrene implants caused extravasation of lymphocytes and neutrophils into the dermis (Fig. 20 B 
& C; H and E staining). Furthermore, PLGA implant could not be found after day 5 (Fig. 20 B; H and 
E staining). High myeloperoxidase activity was observed in response to PLGA implants on day 2 
which decreased with time due to implant resorption. Myeloperoxidase was present inside and in 
surroundings of the implant (Fig. 20 B; Myeloperoxidase). However, macrophages could be seen 
surrounding the PLGA implant on day 2 and persisted till day 8 even after resorption of PLGA 
implant (Fig. 20 B; IBA-1). This might be anti-inflammatory activity of macrophages where they clear 
the debris of implant and apoptotic inflammatory cells to resolve the inflammation. In contrast, 
polystyrene implants are non-degradable and could be seen up to 8 days (Fig. 20 C; H and E). 
Myeloperoxidase and macrophages were present in response to polystyrene implants up to 8 days. 
This demonstrated the chronic inflammatory response to polystyrene implants (Fig. 20 C). 
Interestingly, a fibrous capsule was observed around the implant which thickened temporally, again 
indicating the severity and chronicity of the inflammation (Fig. 20 C; H and E; blue arrows). 
Polystyrene microspheres induced a chronic inflammatory response which is in accordance to in vivo 
imaging data (Fig. 20 C & 19 A). The resolution of PLGA induced inflammation was observed to be 
dependent on the resorption of implant material. Therefore, PLGA implants induced acute 
inflammatory response (Fig. 20 B & 19 A).  
 
Histological analysis was in agreement with results from in vivo imaging of bioluminescent immune 
cells. We observed higher inflammatory potential of polystyrene implants compared to PLGA 
implants which was already shown in vivo using bioluminescent immune cells. This evidenced the 
potential of test system to rank inflammatory potential of implant materials reliably and accurately.  
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Figure 20: Increased inflammatory burden in response to polystyrene implants. Mouse skin tissues with 
injected PBS (A) PLGA (B) and polystyrene (C) microspheres were excised at days 2, 5 and 8 and stained using 
hematoxylin and eosin stain, anti IBA-1 and anti-myeloperoxidase antibody. Hematoxylin and eosin stained 
images are 10X where as IBA-1 and myeloperoxidase stained images are of 20X magnification. ‘i’ represents the 
implant, blue arrow in H & E  images (C) represents the fibrosis layer. 
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6.3  Monitoring Infection 
6.3.1 Detection of innate immune responses to bacterial infections on implants 
 
Implant infections are a serious concern in health care [198].  Microbial infections on implants are 
extremely difficult to treat. Early detection is essential for better treatment. Therefore, a reliable and 
sensitive detection method of high value was required. To this end, a transgenic reporter mouse was 
used. The genetic design of the animal involves the replacement of one allele of interferon-β (IFN-β) 
gene by luciferase gene [186]. The interferon-β gene can be activated by various infectious pathogens 
such as bacteria [184, 185]. To induce an inflammatory response titanium implants were coated with 
heat inactivated bacteria. IFN-β production was detected in response to bacterial extracts on the 
implant after a short delay of 6 hours and remained detectable for more than 24 hours (Fig. 21 A). 
Signals induced by bacteria were 10-fold higher when compared to the bare titanium implant (Fig. 21 
B). Therefore, with this assay we could clearly and reproducibly detect and localize bacteria while 
uninfected control implants did not give a detetcable signal (Fig. 21 A). Inducers of IFN-β are 
infection related molecules such as DNA, bacterial lipopolysachcharides (LPS) or RNA of 
microorganisms which makes the detection system specific for infections whereas various sterile 
implant materials did not activate interferon-β [184, 185]. Reports also suggest that mammalian DNA 
or RNA which could be released from dead cells can also induce interferons [199] but here the injury 
alone was not detected suggesting that this was a minor inflammatory pathway during implantation.  
 
Figure 21: Sensitive detection of bacterial infections on implants:  Interferon-β reporter mice were implanted 
with sterile and infected implants. Bioluminescent imaging was done after implantation and luciferin injection 
RESULTS 
 
54 
 
(A). Implants are as follows: 1. Titanium implant 2 and 3. Titanium implant coated with heat killed (HK) 
bacteria. The relative radiance was calculated and the radiance of the control implant was arbitrarily set to 1 (B). 
6.3.2 In vivo labelling of bacteria to monitor infections  
 
To develop a sensitive detection system that responds solely to infections, it was essential to target 
bacteria in vivo. For this, a compound was needed that could specifically label bacteria in vivo. This 
method will be useful for imaging and treatment of bacterial infections in clinics. To this end, a novel 
compound was synthesized which is a 1,4,7,10 -tetraazacyclododecane-1,4,7,10-tetraacetic acid amide 
(DOTAM) derivative. This compound was linked to siderophores, iron complexing molecules. 
Bacteria need iron as limiting factor for bacteremia. Pseudomonas aeruginosa recognizes a diverse set 
of siderophores and can utilize these compounds for iron acquisition. Interferon-β luciferase reporter 
mice were infected subcutaneously using pseudomonas aeruginosa. Siderophore containing agents 
were linked to Cy5.5 molecules, so we will call them DOTAM-Cy5.5. This compound was injected in 
mice with or without bacteria and monitored for 24 hours (Fig. 22 A). The fluorescence intensity of 
the DOTAM-Cy5.5 was the highest at the site of bacterial injection till 3 hours and the intensity 
decreased gradually (Fig. 22 A). Moreover, the compound without siderophores (DOTA-Cy5.5) was 
also visible at the site of bacteria but with weaker intensity than siderophore linked compound (Fig. 22 
B). To co-localize the immune response to bacteria and the DOTAM-Cy5.5 compound, 
bioluminescent imaging was performed in the same mice by visualizing IFN-β production in response 
to bacterial infection. Mice injected with the DOTAM-Cy5.5 and DOTA-Cy5.5 showed luminescent 
signals at the bacterial injection site (Fig. 22 C and D). The organ imaging of mice revealed that 
DOTAM-Cy5.5 was accumulated in liver and kidneys of the mouse and in spleen to some extent after 
24 hours which showed lower specificity of the compound (Fig. 23 B). No accumulation of DOTA-
Cy5.5 was observed in any of the organs after one day (Fig. 23 C).   
 
Nevertheless, the siderophore linked compounds were able to label bacteria in vivo that was evidenced 
from co-localized signals of compound and immune responses to bacteria. This indicates that 
siderophore agents can target bacteria and can be used as therapeutic carrier to eliminate infections. 
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Figure 22: Real time monitoring of bacteria using fluorescent siderophore agents: P.aeruginosa (PA01 
WT) was subcutaneously injected at the back of interferon-β luciferase reporter mouse. Control mice without 
bacterial infection were included. Mice were injected intravenously with Cy5.5 conjugated compound containing 
siderophore (DOTAM-Cy5.5) (A) and control group was injected with compound without siderophores DOTA-
Cy5.5 only (B). Fluorescent imaging was performed and monitored for a day (A and B). Bioluminescent imaging 
of mice was done after 5 hours by injecting luciferin; mice with DOTAM-Cy5.5 (C) and DOTA-Cy5.5 alone 
(D). Dashed circles in white represent the site of bacterial infection. 
 
 
Figure 23:  Accumulation of DOTAM-Cy5.5 in liver and kidneys: Control mice without bacterial infection 
but injected with DOTAM-Cy5.5 and DOTA-Cy5.5 as a non-specific control were sacrificed after 24 hours and 
organs were imaged to detect fluorescence. Organs from the mouse without any compound injection or infection 
was used as reference mouse to subtract the auto fluorescence from the organs (A). Organs of mice with 
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DOTAM-Cy5.5 compound (B) and DOTA-Cy5.5 alone (C) were imaged to detect siderophore associated 
fluorescence.  
 
6.4  Unexpected longevity of neutrophils  
 
This is a preliminary study related to our surprising finding about the bone marrow derived 
neutrophils. Neutrophils are the main cells of the innate immune system with a short half-life of few 
hours in circulation [200]. Here, we purified neutrophils from bone marrow of luciferase expressing 
mice using neutrophil isolation kit. Purified cells were mainly Ly6G+/Ly6Cint which represents 
neutrophil markers so we called them neutrophils. However, upon adoptive transfer of these cells in 
inflammation mouse model, we observed their survival for 19 days which is unexpected longevity of 
neutrophils. One possibility is the presence of monocytes as side population which is Ly6G-/Ly6Chi 
cells. To confirm the possibility, we did a pre-characterization of neutrophil representing cells. 
6.4.1 Growth factor mediated prolonged survival of neutrophils in vitro 
 
In order to understand the behavior of isolated labelled neutrophil like population, it was essential to 
get pure neutrophil cells. Specific surface markers Ly6G and Ly6C were used to stain the MACS 
purified neutrophils from bone marrow of luciferase expressing mice and the two populations were 
observed; Ly6G+/Ly6Cint and Ly6G-/Ly6Chi (possibly monocytes) which were then separated using 
cell sorter on Ly6G and Ly6C basis (Fig. 24 A). Purified neutrophil cells Ly6G+/Ly6Cint were cultured 
in presence and absence of granulocyte macrophage colony stimulating factor (GM-CSF). This growth 
factor is highly expressed during inflammation and is known to prolong the survival of granulocytes 
and helps in differentiation of the precursor cells [201]. Cell viability was measured using the 
luciferase expression of neutrophils. In the presence of GM-CSF, luminescence from neutrophils could 
be measured for 5 days while unstimulated cells underwent apoptosis within 2 days (Fig. 24 B). Life 
span of pure neutrophils in presence of a stimulus was improved. The growth factor mediated 
longevity of neutrophils was previously shown but in this study luminescent labelled neutrophils 
facilitated the study for extended period of time. Here, we speculate that the prolonged survival of 
neutrophils in vivo could be due to growth factors secreted during inflammation. 
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Figure 24: Growth factor induced prolonged survival of neutrophils: MACS purified neutrophils from the 
bone marrow of luciferase expressing mice were stained for surface markers, Ly6G and Ly6C. Two populations; 
Ly6G+/Ly6Cint and Ly6G-/Ly6Chi were separated using cell sorter (A). Ly6G+/Ly6Cint population was cultured in 
presence and absence of GM-CSF. Relative luminescence units were measured by adding substrate for luciferase 
and values were obtained in plate reader (B).  
6.4.2 Confirmation of longevity of neutrophils in presence of GM-CSF 
 
The aim of present work was to confirm our observation about growth factor induced prolonged 
survival of neutrophils by visualizing viability of cells in inflammatory or non-inflammatory 
conditions. To this end, sorted neutrophil representing cells Ly6G+/Ly6Cint and side monocyte 
population Ly6G-/Ly6Chi were cultured in presence or absence of GM-CSF and live dead staining was 
performed. Neutrophil representing cells appeared to survive for 8 days in presence of growth factor as 
compared to the unstimulated population (Fig. 25 A). In presence of GM-CSF, there was a decrease in 
neutrophil number with time but still viable cells could be seen on day 8 which showed their 
prolonged survival (Fig. 25 A; +GM-CSF; day 8). However, unstimulated neutrophils were mostly 
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dead and washed after 2 days which was expected (Fig 25 A; -GM-CSF; day 4). Side population of 
monocytes when cultured in presence of GM-CSF seemed to behave as macrophages because the cells 
appeared larger in size at later time points (Fig 25 B; day 6 and day 8). Numerous dead monocytes 
were observed in absence of stimulus and the culture was lost after two days (Fig. 25 B; -GM-CSF; d1 
and d2). These results showed a clear difference in the survival time of neutrophils in presence versus 
absence of growth factor. From these results, we also ruled out possible effect of contaminating 
monocytes in purified neutrophils. This confirms that growth factors are inducing some changes in 
neutrophils that were responsible for their prolonged survival. However, the reason for prolonged 
survival in inflamed tissue is still unclear which needs more investigation. 
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Figure 25: GM-CSF mediated prolonged survival of neutrophils and monocytes in cell culture: Neutrophils 
or Ly6G+/Ly6Cint cells (A) and side population of monocytes in the neutrophil population; Ly6G-/Ly6Chi (B) 
were sorted and cultured in absence (-GM-CSF) and presence (+GM-CSF) of growth factor. Live dead staining 
was performed indicating, green cells to be the live cells and red dots are the dead cells. The magnification of 
images is 100X. 
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6.4.3 Change in phenotype of bone marrow derived neutrophils induced by GM-CSF 
 
To understand the unusual longevity of neutrophils, it was essential to check phenotype of the cells in 
presence or absence of stimulus. To this end, bone marrow derived neutrophils from luciferase 
expressing mice were checked for their typical surface markers after culturing them in GM-CSF. The 
purified neutrophil population was Ly6G+/Ly6Cint population on day 0. The results showed that 
neutrophils gradually lose their typical phenotypic markers. Cultured neutrophils in the presence of 
GM-CSF started losing Ly6C surface marker (Fig. 26; d6) and then by day 8 a small percentage of 
cells are double negative (Fig. 26). Studies have shown that neutrophils altered their phenotype more 
oriented towards macrophage like cells in presence of growth factors or cytokines [202, 203]. These 
results also indicated the possible transformation of Ly6G+/Ly6Cint to some other cell type but the 
phenotypic and functional characterization of transformed cells needs further investigation. 
 
 
 
Figure 26: Gradual loss of typical surface markers of neutrophils cultured in the presence of GM-CSF: 
Ly6G+/Ly6Cint population was sorted to achieve high purity of neutrophils. These cells were cultured in presence 
of GM-CSF for 8 days and were stained for Ly6G and Ly6C surface markers and FACS analysis was done.  
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7. Discussion 
 
The focus of the study was to establish a detection method that can distinguish inflammatory potential 
of biomaterials. This detection method will allow evaluating biocompatibility of novel materials and 
will help in development of optimal materials. The strategy was to detect inflammatory products in 
tissue by non-invasive imaging. Inflammatory products were targeted using fluorescent reporter 
molecules and with this strategy inflammatory implants could be differentiated from biocompatible 
materials. However, the signal was delocalized and close to background. Fluorescent imaging 
generally suffers from high background and autofluorescene of tissue. We needed a reproducible assay 
that can show clear differences in the signal intensities to differentiate inflammatory potential of 
materials. Materials chosen for the approach were inflammatory at varying degrees. The upmost 
inflammatory response comes from infection. Infection is a major problem and not easy to detect in 
clinics. Detecting infections at early stages will help in effective treatment. Therefore, bioluminescent 
immune cells were used that allowed to differentiate inflammatory and non-inflammatory materials 
and clearly distinguished infections. This is a reliable method to evaluate biocompatibility of materials 
before introducing them into clinics. Further discussion will be focused on the several strategies used 
to detect inflammation and their limitations, advantages of bioluminescent imaging over fluorescent 
imaging, differentiating inflammatory potential of materials using bioluminescent cells and alternative 
strategies to monitor infections.  
 
7.1  Detection of inflammatory materials by fluorescent imaging 
 
To detect differences in the inflammatory potential of implants, several inflammatory products have 
been targeted using different approaches enabling their visualization in vivo. Macrophages and 
neutrophils release numerous inflammatory products such as reactive oxygen species, cytokines and 
chemokines in response to inflammatory biomaterial [70]. Reactive oxygen radicals produced during 
inflammation were visualized using hydrocyanines [45]. The reduced form of hydrocyanines was 
weakly fluorescent due to disrupted π conjugation but on oxidation it becomes fluorescent and could 
be visualized in near infra-red region [45]. The fluorescence could be correlated to the amount of ROS 
produced in response to inflammatory stimulus. Inflammatory or infected implants could be detected 
and differentiated from the biocompatible implants after local application of hydrocyanine. The 
oxidation potential of the hydrocyanines also seemed to be dependent on diffusion through the tissue, 
which could be the reason for variability of responses in independent experiments. Some degree of 
ROS activity could be seen for the sham surgery which was comparable to the biocompatible implant 
suggesting that ROS production was in response to injury and not due to the implant. The systemic 
administration of the hydrocyanine was unable to reach the inflammation site and showed 
accumulation in organs which could be due to limited diffusion properties of the compound. Though 
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the system was able to differentiate the inflammatory potential of the implants but reliability and 
specificity seemed to be compromised. Chemiluminescent agents such as luminol or L-012 can also be 
used to detect oxygen radicals [49, 204]. Luminol is a redox sensitive compound that emits blue light 
upon oxidation and can be visualized by bioluminescent imaging. It is easily distributed and 
eliminated from the body due to its small size. This makes it a better probe for detection of oxygen 
radicals [205]. However, the oxidizing agent of the compound is unknown and it reacts with many 
reactive oxygen radicals released during phagocytic oxidative burst that limits specificity of the 
compound [205]. It is essential to improve the sensitivity of the existing ROS detecting agents or to 
develop novel compounds that can reliably detect inflammation associated oxygen radicals.  
 
Inflammatory proteases were also considered as potential target to visualize inflammation. Implant 
associated inflammatory process involves the accumulation of inflammatory cells at the implantation 
site and these cells produce degradative enzymes such as proteases to amplify the response [70]. 
Cathepsins are lysosomal proteases that are released by macrophages in pathological conditions such 
as rheumatoid arthritis, cancer, bronchial asthma and obesity [206-209]. These proteases have 
physiological role in apoptosis, protein degradation and antigen presentation. Moreover, the resolution 
of inflammation involves the apoptosis of inflammatory cells that indicates a major role of cathepsins 
in innate immune response [178]. To visualize the cathepsin activity in response to inflammatory 
stimulus, a cathepsin-activatable probe was used. The probe is fluorescent when internalized by the 
cells and cleaved by cathepsins with in lysosomes. Temporal increase in fluorescence showed the 
production of cathepsins in response to infected implants. However, the signal was delocalized and 
fluorescence intensity could not be precisely assigned to a single implant. Cathepsin B and L are 
cysteine proteases and have their function in inflammation and cholesterol trafficking [210]. The probe 
was shown to be activated by cathepsin B, L, S and K by the manufacturer suggesting non-specific 
activation and fluorescence which could be the reason for delocalized signals. Although, in a previous 
study cathepsin-activatable fluorophore was shown to evaluate the biocompatibility of injected 
biomaterials but some extent of delocalization of fluorescence was observed which confirms results of 
this study. In conclusion, this method did not appear to be suitable to distinguish inflammatory 
potential of different implants.  
 
The approach to monitor cell growth stimulating signals has been used to detect tumors and is also 
expected to be involved in wound healing process [211]. Autotaxin is lipase that generates a lipid 
signaling molecule which is responsible for cell motility, viability, proliferation and migration [179]. 
Implant associated inflammation also involves the migration of inflammatory cells to the inflammation 
site followed by proliferation of fibroblasts to form a fibrous capsule surrounding the implant. To 
monitor the autotaxin activity, an analogue of autotaxin substrate lysophosphatidylcholine (LPC) was 
used. The substrate was conjugated to near infra-red fluorophore that produced fluorescence when 
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cleaved by autotaxin. The fluorescence intensity indicated amount of autotaxin produced in response 
to inflammation. Autotaxin associated fluorescence increased with time in response to bacterial 
components on implants. However, the signals were hardly detected because of the high background. 
In addition the signal intensity increased even in absence of implants that indicates the unspecific 
activation of substrate. Therefore, this strategy was unable to determine the extent of inflammation in 
response to individual implants.  
 
Strategies for visualizing enzymatic activities or presence of reactive molecules using fluorescent 
probes generally suffer from high background due to autofluorescence of tissue as well as background 
fluorescence of the probe. Consequently, fluorescent imaging and fluorescent inflammatory reporter 
molecules were unable to fulfil the purpose of distinguishing inflammatory and biocompatible 
implants. Given the limitations of these strategies, there is no animal model that can quantify the 
inflammation in accordance to the clinical relevance 
 
7.2  Bioluminescent imaging versus fluorescent imaging 
 
 In vivo optical imaging is extremely useful technique to monitor implant related inflammation or 
infection because it does not involve animal killing and fate of single implant can be recorded over 
time. The major advantage of non-invasive optical imaging is that each animal can serve as internal 
controls thereby, avoiding even subtle differences in the handling and animal to animal variability. It 
is relatively cheaper and less complex when compared to other imaging modalities such as 
PET/SPECT and MRI [212, 213]. However, spatial resolution of the images is low and dependent 
upon the depth of the desired tissue [213].  
 
Optical imaging can detect photons emitted from the tissues by the fluorescent or bioluminescent 
source. Fluorescent imaging involves the excitation of the fluorescent molecule at desired wavelength 
to visualize the emitted light from the tissues [214]. Alternatively, bioluminescent light can be 
detected as a response of a chemical reaction in the presence of luciferase enzymes [215]. Fluorescent 
imaging unlike bioluminescent imaging has higher background due to autofluorescence from the 
tissues which limited the visualization of the signal from a single implant. The exponential decrease of 
light with the increasing depth of the tissue limits its application to superficial imaging [213]. 
Moreover, the opaque implants quenched the fluorescence emitted and made the detection system 
dependent upon the opacity of materials. The fluorescent imaging technique is in insensitive and non-
specific due to high background signals. In contrast, bioluminescent imaging technique does not 
require an external light source and has extremely low background. This can enable the visualization 
of localized inflammatory responses to each implant. Moreover, the precise quantification of the signal 
can be possible due to high imaging contrast. In addition, this method is well suited for kinetic 
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analysis as the luciferin substrate for firefly luciferase enzymes has a short half-life of approximately 3 
hours [216]. This technique has high signal to noise ratio which made the imaging technique sensitive 
and specific [217]. 
 
Our standards for a detection method were high and we required a precise and accurate method to 
evaluate inflammatory potential of different biomaterials. Therefore, we used bioluminescent immune 
cells to visualize local inflammation in response to biomaterials. 
 
7.3  Monitoring inflammation using bioluminescent immune cells 
 
To evaluate inflammatory potential of biomaterials, a reliable test system was needed. Bioluminescent 
immune cells improved the sensitivity of the detection method for two reasons. Firstly, because of 
bioluminescent imaging that enabled visualization of localized tissue response and secondly, immune 
cells have extremely precise ability to sense and respond to inflammatory stimulus. We could clearly 
differentiate varying degrees of inflammation ranging from highly inflammatory or infected material 
to biocompatible implants.  
 
To enable the detection of immune cells in vivo has always been a big challenge. The labelling of the 
immune cells can be achieved either by direct labelling using probes that can be internalized by the 
immune cells or by genetic modification of cells that results in expression of the reporter protein. The 
former strategy is simple and is used in clinics. However, the efficiency of the technique depends upon 
the ability of cells to retain the label and can only be used to label terminally differentiated cells. 
Furthermore, the label can be lost due to its dilution at each mitotic event that disables long term 
monitoring of cell viability and proliferation [218]. We needed a reliable detection method for 
extended period of time which could be achieved by exploiting the genetically modified cells. To this 
end, immune cells were harvested from a transgenic mouse with substantial constitutive luciferase 
expression under the influence of an inducible Mx-2 promoter [180]. The potential inducers of Mx-2 
promoter activity are infection related cytokines, type I and type III interferons [181]. These cytokines 
have originally been discovered as part of antiviral response but type I interferons are also induced by 
different bacteria [182, 184]. This way we developed a two component system in which immune cells 
were luminescent and detectable in vivo and secondly the luminescence could be enhanced after 
induction of promoter activity during bacterial infections. This genetic design helped in reliable 
monitoring of the cells for longer period of time. In addition, to visualize immune cells in vivo 
bioluminescent imaging was required which facilitated quantification of signals due to high signal to 
background ratio and therefore a distinct difference between bacteria coated and non-inflammatory 
implants was observed. 
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The transferred bioluminescent immune cells were recruited at the implantation site and could 
differentiate implants coated with bacterial components from the biocompatible implants. Amongst 
isolated total bone marrow cells, monocytes and neutrophils, total bone marrow cells showed a larger 
difference in signals and were able to distinguish infected implants and sterile implants. The larger 
difference observed might be due to the presence of progenitor cells or other immune cells in total 
bone marrow fraction which have the ability to proliferate and differentiate in response to 
inflammatory stimulus.  
 
In conclusion, total bone marrow fraction had the optimal cells to evaluate the inflammatory potential 
of biomaterials and was further used to investigate the inflammatory potential of different 
biomaterials. 
7.3.1 A definitive ranking of inflammatory potential of biomaterials 
 
We were able to rank different biomaterials according to their inflammatory potential using 
luminescent labelled immune cells. Biomaterials need testing before their use in clinics. Materials that 
were chosen for the study were already evaluated for their biocompatibility in other studies. We 
selected different biomaterials with different degrees of inflammatory potential. This helped us in 
determining the efficiency and reliability of the detection method. 
 
Poly (lactide-co-glycolic acid) is a biodegradable copolymer of poly glycolic acid (PGA) and poly 
lactic acid (PLA). The major applications of the polymer are known in fabrication of the devices for 
orthopedic surgery, tissue engineering and drug delivery [219]. The polymer undergoes degradation by 
hydrolyzing the ester bond into acidic monomers. The acidic by products create a local low pH 
environment thereby stimulating inflammatory response and affecting cellular growth and function 
[220]. Our observation in the test model using bioluminescent immune cells confirms the 
inflammatory potential of PLGA. In other study, production of reactive oxygen species in response to 
PLGA was visualized using hydrocyanines and non-invasive imaging [45]. To dampen the 
inflammatory response to PLGA, several modifications have been done such as incorporation of anti-
inflammatory drugs like dexamethasone or by blending PLGA with magnesium hydroxide 
nanoparticles to neutralize the pH which may improve the cell viability and minimize the 
inflammatory reactions [221, 222].  
 
On the other hand, biocompatible titanium implants are standard biomaterials and are used in clinics 
for decades. They have a broader range of applications as dental and orthopedic implants, prosthetic 
heart valves and protection cases for pacemakers. Titanium receives extensive attention because of its 
appropriate mechanical performance, great tensile strength, and high resistance to corrosion and most 
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importantly excellent biocompatibility [223, 224]. Due to its high standards of biocompatibility, 
titanium was a good negative control in the testing system. 
  
Magnesium is an extremely low weight metal that was first discovered as orthopedic implants. It is 
biodegradable and biocompatible biomaterial and has the ability to stimulate bone growth and healing. 
However, the major limitation of magnesium is its low resistant to corrosion that limited its further use 
in orthopedics. The magnesium based implants degrade rapidly in physiological environment and 
produce corrosion particles. Interestingly, these wear particles are harmless and are eliminated from 
the body through urine [225, 226]. Moreover, the gene expression patterns of tissue surrounding 
magnesium and titanium implant were similar which indicates its biocompatibility in vivo [227]. The 
magnesium implants were monitored in our animal test system and biocompatibility of magnesium 
was comparable to titanium implants. Our study lies in accordance to other biocompatibility studies on 
magnesium.  
 
Inflammatory biomaterials were differentiated from the known biocompatible biomaterials by imaging 
bioluminescent immune cells. The ability of the detection system to evaluate the inflammatory 
potential of different biomaterials indicated higher sensitivity of the system when compared to other 
animal test systems where fluorescent inflammatory reporter molecules were used. This 
bioluminescent imaging strategy allowed reliable visualization and quantification of biomaterial 
associated inflammation. 
7.3.2 Material induced inflammation versus injury 
 
Injury elicits inflammation. To this end, injectable biomaterials were used that stimulate minimum 
tissue injury and can be used to evaluate material induced inflammation. Injectable biomaterials are 
widely used in drug delivery and tissue engineering. Here, we were able to rank the inflammation in 
response to injectable materials using luminescent labelled cells. Materials were chosen according to 
their bio-degradability in physiological environment. 
  
Polymeric microspheres are one form of injectable materials that are used as controlled drug delivery 
agents, filler agents to restore tissue volume and embolic particles to occlude vessels of tumors. The 
controlled shape and size of the microspheres makes them ideal injectable biomaterial. Microspheres 
in circulation should be biocompatible, perform desired function and have predictable degradation 
kinetics [228]. They have been tested in animal models to assess their inflammatory potential. 
Cathepsin activity was observed in response to polystyrene microspheres of size 3 µm that suggests 
the presence of macrophages and neutrophils that attempt to internalize and degrade the microspheres 
[54]. In this study we showed the dependency of immune response on the degradability of 
microspheres. Polystyrene microspheres (1 µm) stimulated chronic inflammatory response due to its 
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non-degradable characteristics. In contrast, biodegradable PLGA microspheres of similar size showed 
acute inflammation which could be due to resorption of the implant. PLGA based biomaterials were 
inflammatory due to its acidic degradation products.  
 
Another injectable material is biodegradable chitosan which is a polysaccharide derived from crab 
shells. The applications of chitosan in biomedical field are in wound dressing and drug delivery. 
Chitosan membranes were also proposed as artificial kidney membranes due to their appropriate 
membrane permeability and high tensile strength but due to its thrombogenic properties it was not put 
into use. It was initially considered as biocompatible but the absolute inertness of chitosan was 
questionable because the immunogenicity of chitosan depends upon its source (crab, shrimps and 
fungus), variability in tertiary structures due to manufacturing processes and degree of contaminants 
[229]. Moreover, chitosan has been shown as potent activator of NLRP3 inflammasome [230, 231]. In 
addition, our animal test system was able to monitor the inflammatory cells recruited in response to 
chitosan. 
 
Traditionally, histology was the detection method to analyze local tissue inflammation in response to 
implants. The technique required more number of animals to follow the inflammation kinetics and 
moreover, processing of the tissue sections involves tedious steps such as fixation, embedding and 
staining. However, we validated our in vivo imaging results using this technique. Here in this study, 
we observed a similar inflammatory response to PLGA and polystyrene implants after histologic 
analysis.  
 
The detection method developed here allowed rapid and reliable in vivo monitoring of implant related 
inflammation. It permitted analysis of foreign body response to different biomaterials thereby, 
eliminating the need of expensive and time consuming histological analysis.  
7.3.3 Application of implant inflammation model 
 
Biomaterial science is an interdisciplinary field where materials scientists work towards the 
improvement of physical and chemical properties of the biomaterials, chemists develop novel 
antibacterial or anti-inflammatory compounds as coatings on biomaterials and biologists screen the 
biocompatibility and functionality of novel materials and coatings. Here, we developed a screening 
method to assess the immune response of novel materials or coatings in real time. This method can 
follow a single implant in vivo and can help in studying the interaction of implants with tissue. 
Moreover, novel or existing anti-inflammatory drugs can be tested and monitored in real time using 
bioluminescent cells. In addition, controlled local drug delivery methods have always been an 
attraction to eliminate implant infections. This model can help in monitoring slow local response of 
the drug for longer period of time. Immune cells are mostly the targets of anti- inflammatory drugs and 
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to monitor their effect using bioluminescent cells will allow their visualization during action. Thus, 
these approaches reveal the clinical benefits of the animal model for implant-related inflammation. 
 
7.4  Implant infections 
Detecting implant infections at early stages is clinically important for effective treatment. These 
infections are mostly resistant to conventional antibiotics and can cause serious complications in the 
host. To treat these infections, there is a need to monitor them in vivo. Here, we used siderophore 
agents to target bacteria in vivo. These siderophores have high iron solubility and are taken up by 
bacteria under iron limiting conditions. We took an advantage of this natural mechanism of bacteria 
and conjugated a fluorophore to the siderophore linked agents for non-invasive imaging. Transgenic 
mice that allow visualization of innate immune response to bacteria were used to confirm the bacterial 
infection by bioluminescent imaging. Fluorescence of the siderophore agents was co-localized with 
bioluminescent innate immune response to bacterial infections, thus confirming the specificity of the 
siderophore compounds to bacteria. This indicates that siderophore agents can target bacteria and can 
be used as therapeutic carrier to eliminate infections. 
 
Diagnosing and treating bacterial infections on implant is a challenge due to lack of accuracy and 
specificity of bacteria targeting compounds. Although numerous bacterial targeting strategies have 
been developed, none could be proven clinically useful. In this study, siderophore based compounds 
demonstrated high specificity due to their uptake by bacteria. Therefore, siderophore drug complexes 
have tremendous potential to treat infections. We demonstrated promising preliminary results of the 
siderophore compounds which need further characterization to show compound uptake by bacteria. 
Moreover, the efficacy of the antibiotic linked to siderophore compounds needs to be tested in vitro 
and in vivo.  
 
7.5  Developmental potential of bone marrow derived neutrophils 
 
We were using isolation procedure based on Ly6G and Ly6C that are specific for neutrophils and 
monocytes which make up the major population in bone marrow. Even though the cells were not 
analyzed, subsequently we will call Ly6G+/Ly6Cint neutrophils and Ly6G-/Ly6Chi monocytes. This 
preliminary study was related to our unexpected findings about neutrophils that showed unusual 
survival time in inflamed tissue. Neutrophils are the main cell types of innate immune system. 
Neutrophils have a short half-life in circulation of 1.5 hours and 8 hours in mice and humans, 
respectively. However, the myth of short lived cells is changing and several studies have shown 
prolonged half-life of neutrophils in circulation under basal conditions which is 12.5 hours and 5.4 
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days in mice and humans respectively [200]. Inflammatory diseases such as acute respiratory distress 
syndrome (ARDS), pneumonia, sepsis, rheumatoid arthritis and cystic fibrosis exhibit delayed 
apoptosis of neutrophils in blood and synovial fluid [232-235]. One of the reasons for delayed 
apoptosis is increased levels of growth factor GM-CSF in sepsis, burns and acute respiratory 
syndrome [232]. In our case, the prolonged survival of neutrophils was first thought to be due to 
dividing monocytes which was present as side population in isolated neutrophils. We ruled out that 
possibility by sorting pure neutrophils from side population. We observed growth factor induced 
prolonged survival of neutrophils in vitro.  
 
Furthermore, as we know neutrophils are produced in bone marrow from a progenitor cell myeloblast 
which then differentiates to promeyelocyte that is committed to neutrophil lineage. Eventually, 
promyelocyte matures to form myelocytes. These three cell types constitute mitotic pool of bone 
marrow in which cells proliferate. When myelocytes produce metamyelocytes, then they constitute 
post mitotic pool and can no longer divide [200]. Recently, a study revealed that post mitotic 
neutrophils can switch the lineage to macrophages in vitro when cultured in presence of appropriate 
growth factors and cytokines [202]. Another similar research showed that neutrophils express 
macrophage specific receptors and have the ability to transdifferentiate to macrophages [203]. In 
support to this, we observed temporal loss of typical phenotype markers of neutrophils when cultured 
in presence of GM-CSF. This could be due to the change in phenotypic characteristics of cells in 
presence of growth factor. It is still unclear that these cells were really transdifferentiating to some 
other cell types or not. However, the phenotypic changes appeared promising to study the possibility 
in detail. If true, this study will change the paradigm of neutrophil research and we can provide an in 
vivo model to study the neutrophil kinetics in inflammation. 
7.5.1 Further characterization of bone marrow immune cells 
 
The preliminary results on the neutrophil survival gave us a different direction on characterization of 
cells in presence of inflammation. Bioluminescent neutrophils isolated from luciferase expressing 
mice allow visualization of cells without extra effort of labelling. Moreover, labelling procedures can 
manipulate neutrophils affecting their kinetics and migration [236]. Bioluminescent neutrophils are 
ideal genetically labelled cells and can help in studying the phenotype and function of bone marrow 
cells in vitro and in vivo. To find out reprogramming ability of neutrophils, we need gene expression 
analysis of neutrophils and macrophages under the influence of cytokines and growth factors. If 
hypothesis of transformation is true in our case, then we will be able to introduce a novel model to 
study dynamics of neutrophils in real time.  
 
CONCLUSION 
 
71 
 
8. Conclusion 
 
The major aim of the study was to evaluate inflammatory potential of novel implant materials in vivo. 
The initial strategy was to detect reactive species of inflammation by fluorescent imaging. Even 
though with these strategies inflammatory events could be detected but the method resulted in high 
background and diffused signal distribution. To improve signal to noise ratio and to get more focused 
signal, bioluminescent labelled cells were used. With this strategy, we were able to distinguish non 
inflammatory materials from inflammatory materials or injury. Moreover, sterile inflammation from 
infections could be distinguished. These results are useful for ranking biocompatibility according to 
the inflammatory potential of implant materials which is essential in developing optimal materials. We 
could observe immune response of different degrees varying from highly inflammatory bacterial 
infections to biocompatible biomaterials. In addition, implant materials of different size and texture 
have different inflammatory responses which could be evaluated and ranked using this method. Early 
detection of infections would allow their effective treatment. This detection method could have 
clinical potential in monitoring infections by replacing optical imaging with MRI or PET scan and by 
scaling up the labelling of human blood cells. As a side finding, immune cells population expressing 
neutrophil markers showed an unexpected longevity which suggests that it is previously 
uncharacterized precursor immune cells population that warrants further investigation. 
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APC Antigen presenting cells 
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ECM Extracellular matrix 
EPS Extracellular polymeric substances 
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G-CSF Granulocyte colony stimulating factor 
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ROS Reactive oxygen species 
Si Silica 
TH T helpers 
TLR Toll like receptors 
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
 
75 
 
9.4  References 
 
1. Freedonia, G., Implantable medical devices to 2014- demand and sales forecast, market share, 
market size, market leaders. 2010. 
2. Black, J. and G. Hastings, Handbook of Biomaterial Properties. 1998: Springer US. 
3. Vacanti, C.A., The history of tissue engineering. J Cell Mol Med, 2006. 10(3): p. 569-76. 
4. Mason, C. and P. Dunnill, A brief definition of regenerative medicine. Regen Med, 2008. 3(1): 
p. 1-5. 
5. Ratner, B.D., Biomaterials Science: An Introduction to Materials in Medicine. 2004: Elsevier 
Academic Press. 
6. Black, M.M., R.v. Noort, and P.J. Drury, Medical applications of biomaterials. Physics in 
Technology, 1982. 13(2): p. 50. 
7. Sanan, A. and S.J. Haines, Repairing holes in the head: a history of cranioplasty. 
Neurosurgery, 1997. 40(3): p. 588-603. 
8. Hansmann, C., Eine neue Methode der Fixierung der Fragmente bei complicierten Fracturen. 
Verh Dtsch Ges Chir, 1886. 15: p. 134-. 
9. Venable, C.S., W.G. Stuck, and A. Beach, The effects on bone of the presence of the metals; 
based upon the electrolysis: an experimental study. Annals of Surgery, 1937. 105(6): p. 917-
938. 
10. Luckey, H.A., et al., Titanium Alloys in Surgical Implants. 1983: American Society for 
Testing & Materials. 
11. Kolff, W.J., The artificial kidney and its effect on the development of other artificial organs. 
Nat Med, 2002. 8(10): p. 1063-1065. 
12. Apple, D.J. and J. Sims, Harold Ridley and the invention of the intraocular lens. Survey of 
Ophthalmology, 1996. 40(4): p. 279-292. 
13. Hench, L.L., Bioactive ceramics. Annals of the New York Academy of Sciences, 1988. 523: 
p. 54-71. 
14. Hench, L.L. and J. Wilson, An Introduction to Bioceramics. 1993: World Scientific. 
15. Walid, H., Drug-eluting stents : Insights into safety and indications. Annals of Saudi 
Medicine, 2008. 
16. Xynos, I.D., et al., Gene-expression profiling of human osteoblasts following treatment with 
the ionic products of Bioglass® 45S5 dissolution. Journal of Biomedical Materials Research, 
2001. 55(2): p. 151-157. 
17. Donaruma, L.G., Definitions in biomaterials, D. F. Williams, Ed., Elsevier, Amsterdam, 1987, 
72 pp. Journal of Polymer Science Part C: Polymer Letters, 1988. 26(9): p. 414-414. 
18. Williams, D.F., The Williams Dictionary of Biomaterials. 1999: Liverpool University Press. 
19. Porter, J.A. and J.A. Von Fraunhofer, Success or failure of dental implants? A literature 
review with treatment considerations. General Dentistry, 2005. 53(6): p. 423-432. 
20. Montanaro, L., D. Campoccia, and C.R. Arciola, Advancements in molecular epidemiology of 
implant infections and future perspectives. Biomaterials, 2007. 28(34): p. 5155-5168. 
21. Gorbet, M.B. and M.V. Sefton, Endotoxin: The uninvited guest. Biomaterials, 2005. 26(34): p. 
6811-6817. 
22. Williams, D.F., On the mechanisms of biocompatibility. Biomaterials, 2008. 29(20): p. 2941-
2953. 
23. Jones, C.A., et al., Total Joint Arthroplasties: Current Concepts of Patient Outcomes after 
Surgery. Clinics in Geriatric Medicine, 2005. 21(3): p. 527-541. 
24. Bruning, N., Breast Implants: Everything You Need to Know. 2002: Hunter House. 
25. Vert, M., J. Mauduit, and S. Li, Biodegradation of PLA/GA polymers: increasing complexity. 
Biomaterials, 1994. 15(15): p. 1209-1213. 
26. Shive, M.S. and J.M. Anderson, Biodegradation and biocompatibility of PLA and PLGA 
microspheres. Adv Drug Deliv Rev, 1997. 28(1): p. 5-24. 
27. Williams, D.F., To engineer is to create: The link between engineering and regeneration. 
Trends in Biotechnology, 2006. 24(1): p. 4-8. 
APPENDIX 
 
76 
 
28. Onuki, Y., et al., A Review of the Biocompatibility of Implantable Devices: Current 
Challenges to Overcome Foreign Body Response. Journal of diabetes science and technology 
(Online), 2008. 2(6): p. 1003-1015. 
29. Ito, A., et al., Zinc-releasing calcium phosphate for stimulating bone formation. Materials 
Science and Engineering: C, 2002. 22(1): p. 21-25. 
30. Webster, T.J., et al., Osteoblast response to hydroxyapatite doped with divalent and trivalent 
cations. Biomaterials, 2004. 25(11): p. 2111-21. 
31. Bennewitz, N.L. and J.E. Babensee, The effect of the physical form of poly(lactic-co-glycolic 
acid) carriers on the humoral immune response to co-delivered antigen. Biomaterials, 2005. 
26(16): p. 2991-2999. 
32. Kirkpatrick, C.J., et al., Current trends in biocompatibility testing. Proc Inst Mech Eng H, 
1998. 212(2): p. 75-84. 
33. Santos, M.H., et al., Biocompatibility evaluation of hydroxyapatite/collagen nanocomposites 
doped with Zn+2. Biomed Mater, 2007. 2(2): p. 135-41. 
34. Brown, S.A., et al., Cell Culture Test Methods. 1983: American Society for Testing and 
Materials. 
35. Ciapetti, G., et al., Application of a combination of neutral red and amido black staining for 
rapid, reliable cytotoxicity testing of biomaterials. Biomaterials, 1996. 17(13): p. 1259-64. 
36. Morrison, C., et al., In vitro biocompatibility testing of polymers for orthopaedic implants 
using cultured fibroblasts and osteoblasts. Biomaterials, 1995. 16(13): p. 987-92. 
37. Kretzmer, E.A., et al., An animal model for cochlear implants. Arch Otolaryngol Head Neck 
Surg, 2004. 130(5): p. 499-508. 
38. Pearce, A.I., et al., Animal models for implant biomaterial research in bone: a review. Eur 
Cell Mater, 2007. 13: p. 1-10. 
39. Todescan, R., Jr., R.M. Pilliar, and A.H. Melcher, A small animal model for investigating 
endosseous dental implants: effect of graft materials on healing of endosseous, porous-
surfaced implants placed in a fresh extraction socket. Int J Oral Maxillofac Implants, 1987. 
2(4): p. 217-23. 
40. Waterston, R.H., et al., Initial sequencing and comparative analysis of the mouse genome. 
Nature, 2002. 420(6915): p. 520-62. 
41. Koschwanez, H.E. and W.M. Reichert, In vitro, in vivo and post explantation testing of 
glucose-detecting biosensors: current methods and recommendations. Biomaterials, 2007. 
28(25): p. 3687-703. 
42. Lindner, E., et al., Ion-selective membranes with low plasticizer content: electroanalytical 
characterization and biocompatibility studies. J Biomed Mater Res, 1994. 28(5): p. 591-601. 
43. Marchant, R., et al., In vivo biocompatibility studies. I. The cage implant system and a 
biodegradable hydrogel. J Biomed Mater Res, 1983. 17(2): p. 301-25. 
44. Kao, W.J., et al., Role for interleukin-4 in foreign-body giant cell formation on a 
poly(etherurethane urea) in vivo. J Biomed Mater Res, 1995. 29(10): p. 1267-75. 
45. Selvam, S., et al., Minimally invasive, longitudinal monitoring of biomaterial-associated 
inflammation by fluorescence imaging. Biomaterials, 2011. 32(31): p. 7785-92. 
46. Suri, S., et al., In vivo fluorescence imaging of biomaterial-associated inflammation and 
infection in a minimally invasive manner. J Biomed Mater Res A, 2015. 103(1): p. 76-83. 
47. Liu, W.F., et al., Real-time in vivo detection of biomaterial-induced reactive oxygen species. 
Biomaterials, 2011. 32(7): p. 1796-1801. 
48. Zhou, J., et al., Noninvasive assessment of localized inflammatory responses. Free radical 
biology & medicine, 2012. 52(1): p. 218-226. 
49. Kielland, A., et al., In vivo imaging of reactive oxygen and nitrogen species in inflammation 
using the luminescent probe L-012. Free Radic Biol Med, 2009. 47(6): p. 760-6. 
50. Daiber, A., et al., Measurement of NAD(P)H oxidase-derived superoxide with the luminol 
analogue L-012. Free Radic Biol Med, 2004. 36(1): p. 101-11. 
51. Daiber, A., et al., Detection of superoxide and peroxynitrite in model systems and 
mitochondria by the luminol analogue L-012. Free Radic Res, 2004. 38(3): p. 259-69. 
52. Lee, D., et al., In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. 
Nat Mater, 2007. 6(10): p. 765-9. 
APPENDIX 
 
77 
 
53. Lee, D., et al., Detection of hydrogen peroxide with chemiluminescent micelles. Int J 
Nanomedicine, 2008. 3(4): p. 471-6. 
54. Bratlie, K.M., et al., Rapid Biocompatibility Analysis of Materials via In Vivo Fluorescence 
Imaging of Mouse Models. PLoS ONE, 2010. 5(4): p. e10032. 
55. Anderson, J.M., Biological responses to materials. Annual Review of Materials Science, 
2001. 31: p. 81-110. 
56. Anderson, J.M., Multinucleated giant cells. Current Opinion in Hematology, 2000. 7(1): p. 40-
47. 
57. Gretzer, C., et al., The inflammatory cell influx and cytokines changes during transition from 
acute inflammation to fibrous repair around implanted materials. Journal of Biomaterials 
Science, Polymer Edition, 2006. 17(6): p. 669-687. 
58. Luttikhuizen, D.T., M.C. Harmsen, and M.J.A. Van Luyn, Cellular and molecular dynamics 
in the foreign body reaction. Tissue Engineering, 2006. 12(7): p. 1955-1970. 
59. Wilson, C.J., et al., Mediation of biomaterial-cell interactions by adsorbed proteins: A review. 
Tissue Engineering, 2005. 11(1-2): p. 1-18. 
60. Steele, J.G., et al., Attachment of human bone cells to tissue culture polystyrene and to 
unmodified polystyrene: the effect of surface chemistry upon initial cell attachment. J 
Biomater Sci Polym Ed, 1993. 5(3): p. 245-57. 
61. Howlett, C.R., et al., Mechanism of initial attachment of cells derived from human bone to 
commonly used prosthetic materials during cell culture. Biomaterials, 1994. 15(3): p. 213-22. 
62. Kilpadi, K.L., P.L. Chang, and S.L. Bellis, Hydroxylapatite binds more serum proteins, 
purified integrins, and osteoblast precursor cells than titanium or steel. J Biomed Mater Res, 
2001. 57(2): p. 258-67. 
63. Takebe, J., et al., Anodic oxidation and hydrothermal treatment of titanium results in a surface 
that causes increased attachment and altered cytoskeletal morphology of rat bone marrow 
stromal cells in vitro. Journal of Biomedical Materials Research, 2000. 51(3): p. 398-407. 
64. Lopes, M.A., et al., Hydrophobicity, surface tension, and zeta potential measurements of 
glass-reinforced hydroxyapatite composites. Journal of Biomedical Materials Research, 1999. 
45(4): p. 370-375. 
65. Hallab, N.J., et al., Evaluation of metallic and polymeric biomaterial surface energy and 
surface roughness characteristics for directed cell adhesion. Tissue Eng, 2001. 7(1): p. 55-71. 
66. Ponsonnet, L., et al., Relationship between surface properties (roughness, wettability) of 
titanium and titanium alloys and cell behaviour. Materials Science and Engineering: C, 2003. 
23(4): p. 551-560. 
67. Steven, M.S. and A.H. Thomas, The Vroman Effect, in Proteins at Interfaces II. 1995, 
American Chemical Society. p. 112-128. 
68. Keselowsky, B.G., et al., Role of plasma fibronectin in the foreign body response to 
biomaterials. Biomaterials, 2007. 28(25): p. 3626-3631. 
69. McNally, A.K., et al., Vitronectin is a critical protein adhesion substrate for IL-4-induced 
foreign body giant cell formation. Journal of Biomedical Materials Research - Part A, 2008. 
86(2): p. 535-543. 
70. Franz, S., et al., Immune responses to implants – A review of the implications for the design of 
immunomodulatory biomaterials. Biomaterials, 2011. 32(28): p. 6692-6709. 
71. Müller, P., Blood Coagulation and Fibrinolysis, in Biochemical Pathways. 2012, John Wiley 
& Sons, Inc. p. 357-365. 
72. Heemskerk, J.W.M., E.M. Bevers, and T. Lindhout, Platelet activation and blood coagulation. 
Thrombosis and Haemostasis, 2002. 88(2): p. 186-193. 
73. Tang, L., Mechanisms of fibrinogen domains: Biomaterial interactions. Journal of 
Biomaterials Science, Polymer Edition, 1998. 9(12): p. 1257-1266. 
74. Hu, W.J., J.W. Eaton, and L. Tang, Molecular basis of biomaterial-mediated foreign body 
reactions. Blood, 2001. 98(4): p. 1231-1238. 
75. Gorbet, M.B. and M.V. Sefton, Biomaterial-associated thrombosis: Roles of coagulation 
factors, complement, platelets and leukocytes. Biomaterials, 2004. 25(26): p. 5681-5703. 
76. Schmaier, A.H., Contact activation: A revision. Thrombosis and Haemostasis, 1997. 78(1): p. 
101-107. 
APPENDIX 
 
78 
 
77. Sperling, C., et al., Blood coagulation on biomaterials requires the combination of distinct 
activation processes. Biomaterials, 2009. 30(27): p. 4447-4456. 
78. Fischer, M., C. Sperling, and C. Werner, Synergistic effect of hydrophobic and anionic surface 
groups triggers blood coagulation in vitro. Journal of Materials Science: Materials in 
Medicine, 2010. 21(3): p. 931-937. 
79. Nilsson, B., et al., The role of complement in biomaterial-induced inflammation. Molecular 
Immunology, 2007. 44(1-3): p. 82-94. 
80. Lhotta, K., et al., Rapid activation of the complement system by cuprophane depends on 
complement component C4. Kidney International, 1998. 53(4): p. 1044-1051. 
81. Hed, J., M. Johansson, and M. Lindroth, Complement activation according to the alternate 
pathway by glass and plastic surfaces and its role in neutrophil adhesion. Immunology 
Letters, 1984. 8(6): p. 295-299. 
82. Tengvall, P., A. Askendal, and I. Lundström, Ellipsometric in vitro studies on the activation of 
complement by human immunoglobulins M and G after adsorption to methylated silicon. 
Colloids and Surfaces B: Biointerfaces, 2001. 20(1): p. 51-62. 
83. Andersson, J., et al., C3 adsorbed to a polymer surface can from an initiating alternative 
pathway convertase. Journal of Immunology, 2002. 168(11): p. 5786-5791. 
84. Sarma, J.V. and P.A. Ward, The complement system. Cell and Tissue Research, 2011. 343(1): 
p. 227-235. 
85. Fischer, M., et al., The ability of surface characteristics of materials to trigger leukocyte tissue 
factor expression. Biomaterials, 2010. 31(9): p. 2498-2507. 
86. Anderson, J.M., A. Rodriguez, and D.T. Chang, Foreign body reaction to biomaterials. 
Seminars in Immunology, 2008. 20(2): p. 86-100. 
87. Bianchi, M.E., DAMPs, PAMPs and alarmins: All we need to know about danger. Journal of 
Leukocyte Biology, 2007. 81(1): p. 1-5. 
88. Agresti, A. and M.E. Bianchi, HMGB proteins and gene expression. Curr Opin Genet Dev, 
2003. 13(2): p. 170-8. 
89. Muller, S., L. Ronfani, and M.E. Bianchi, Regulated expression and subcellular localization 
of HMGB1, a chromatin protein with a cytokine function. J Intern Med, 2004. 255(3): p. 332-
43. 
90. Scaffidi, P., T. Misteli, and M.E. Bianchi, Release of chromatin protein HMGB1 by necrotic 
cells triggers inflammation. Nature, 2002. 418(6894): p. 191-5. 
91. Qin, S., et al., Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med, 2006. 
203(7): p. 1637-42. 
92. Dumitriu, I.E., et al., HMGB1: guiding immunity from within. Trends Immunol, 2005. 26(7): 
p. 381-7. 
93. Yang, D., et al., High mobility group box-1 protein induces the migration and activation of 
human dendritic cells and acts as an alarmin. J Leukoc Biol, 2007. 81(1): p. 59-66. 
94. Dumitriu, I.E., et al., The secretion of HMGB1 is required for the migration of maturing 
dendritic cells. J Leukoc Biol, 2007. 81(1): p. 84-91. 
95. Foell, D., et al., S100 proteins expressed in phagocytes: a novel group of damage-associated 
molecular pattern molecules. J Leukoc Biol, 2007. 81(1): p. 28-37. 
96. Schmitt, E., et al., Intracellular and extracellular functions of heat shock proteins: 
repercussions in cancer therapy. J Leukoc Biol, 2007. 81(1): p. 15-27. 
97. Kobayashi, S.D., et al., Neutrophils in the innate immune response. Archivum Immunologiae 
et Therapiae Experimentalis, 2005. 53(6): p. 505-517. 
98. Nimeri, G., et al., The influence of plasma proteins and platelets on oxygen radical production 
and F-actin distribution in neutrophils adhering to polymer surfaces. Biomaterials, 2002. 
23(8): p. 1785-1795. 
99. Labow, R.S., E. Meek, and J.P. Santerre, Neutrophil-mediated biodegradation of medical 
implant materials. Journal of Cellular Physiology, 2001. 186(1): p. 95-103. 
100. Scapini, P., et al., The neutrophil as a cellular source of chemokines. Immunological Reviews, 
2000. 177: p. 195-203. 
101. Yamashiro, S., et al., Phenotypic and functional change of cytokine-activated neutrophils: 
Inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. 
Journal of Leukocyte Biology, 2001. 69(5): p. 698-704. 
APPENDIX 
 
79 
 
102. Martinez, F.O., et al., Macrophage activation and polarization. Frontiers in Bioscience, 2008. 
13(2): p. 453-461. 
103. Mosser, D.M. and J.P. Edwards, Exploring the full spectrum of macrophage activation. Nature 
Reviews Immunology, 2008. 8(12): p. 958-969. 
104. Stein, M., et al., Interleukin 4 potently enhances murine macrophage mannose receptor 
activity: A marker of alternative immunologic macrophage activation. Journal of 
Experimental Medicine, 1992. 176(1): p. 287-292. 
105. Xia, Z. and J.T. Triffitt, A review on macrophage responses to biomaterials. Biomedical 
Materials, 2006. 1(1): p. R1-R9. 
106. DeFife, K.M., et al., Interleukin-13 Induces Human Monocyte/Macrophage Fusion and 
Macrophage Mannose Receptor Expression. Journal of Immunology, 1997. 158(7): p. 3385-
3390. 
107. Kao, W.J., et al., Role for interleukin-4 in foreign-body giant cell formation on a 
poly(etherurethane urea) in vivo. Journal of Biomedical Materials Research, 1995. 29(10): p. 
1267-1275. 
108. McNally, A.K. and J.M. Anderson, Interleukin-4 induces foreign body giant cells from human 
monocytes/macrophages: Differential lymphokine regulation of macrophage fusion leads to 
morphological variants of multinucleated giant cells. American Journal of Pathology, 1995. 
147(5): p. 1487-1499. 
109. Xia, Z.D., et al., Macrophages in degradation of collagen/hydroxylapatite(CHA), beta-
tricalcium phosphate ceramics (TCP) artificial bone graft. An in vivo study. Chinese Medical 
Journal, 1994. 107(11): p. 845-849. 
110. Christenson, E.M., J.M. Anderson, and A. Hiltner, Oxidative mechanisms of poly(carbonate 
urethane) and poly(ether urethane) biodegradation: In vivo and in vitro correlations. Journal 
of Biomedical Materials Research - Part A, 2004. 70(2): p. 245-255. 
111. Santerre, J.P., et al., Understanding the biodegradation of polyurethanes: From classical 
implants to tissue engineering materials. Biomaterials, 2005. 26(35): p. 7457-7470. 
112. Zhao, Q.H., et al., Human plasma α2-macroglobulin promotes in vitro oxidative stress 
cracking of Pellethane 2363-80A: In vivo and in vitro correlations. Journal of Biomedical 
Materials Research, 1993. 27(3): p. 379-388. 
113. Kao, W.J., et al., Theoretical analysis of in vivo macrophage adhesion and foreign body giant 
cell formation on polydimethylsiloxane, low density polyethylene, and polyetherurethanes. 
Journal of Biomedical Materials Research, 1994. 28(1): p. 73-79. 
114. Broughton, G., 2nd, J.E. Janis, and C.E. Attinger, The basic science of wound healing. Plast 
Reconstr Surg, 2006. 117(7 Suppl): p. 12s-34s. 
115. Eming, S.A., T. Krieg, and J.M. Davidson, Inflammation in wound repair: Molecular and 
cellular mechanisms. Journal of Investigative Dermatology, 2007. 127(3): p. 514-525. 
116. Chu, C.C., J.A. von Fraunhofer, and H.P. Greisler, Wound Closure Biomaterials and Devices. 
1996: Taylor & Francis. 
117. Ratner, B.D., The Engineering of Biomaterials Exhibiting Recognition and Specificity. Journal 
of Molecular Recognition, 1996. 9(5-6): p. 617-625. 
118. Rungsiyakull, C., et al., Surface morphology optimization for osseointegration of coated 
implants. Biomaterials, 2010. 31(27): p. 7196-7204. 
119. Dinnes, D.L.M., et al., Material surfaces affect the protein expression patterns of human 
macrophages: A proteomics approach. Journal of Biomedical Materials Research - Part A, 
2007. 80(4): p. 895-908. 
120. Jones, J.A., et al., Proteomic analysis and quantification of cytokines and chemokines from 
biomaterial surface-adherent macrophages and foreign body giant cells. Journal of 
Biomedical Materials Research - Part A, 2007. 83(3): p. 585-596. 
121. Yim, E.K.F. and K.W. Leong, Significance of synthetic nanostructures in dictating cellular 
response. Nanomedicine: Nanotechnology, Biology, and Medicine, 2005. 1(1): p. 10-21. 
122. Fink, J., et al., Stimulation of monocytes and macrophages: Possible influence of surface 
roughness. Clinical Hemorheology and Microcirculation, 2008. 39(1-4): p. 205-212. 
123. Chen, S., et al., Characterization of topographical effects on macrophage behavior in a 
foreign body response model. Biomaterials, 2010. 31(13): p. 3479-3491. 
APPENDIX 
 
80 
 
124. Hersel, U., C. Dahmen, and H. Kessler, RGD modified polymers: Biomaterials for stimulated 
cell adhesion and beyond. Biomaterials, 2003. 24(24): p. 4385-4415. 
125. Shin, H., S. Jo, and A.G. Mikos, Biomimetic materials for tissue engineering. Biomaterials, 
2003. 24(24): p. 4353-4364. 
126. Kao, W.J., et al., Fibronectin modulates macrophage adhesion and FBGC formation: The role 
of RGD, PHSRN, and PRRARV domains. Journal of Biomedical Materials Research, 2001. 
55(1): p. 79-88. 
127. Kao, W.J. and Y. Liu, Utilizing biomimetic oligopeptides to probe fibronectin-integrin binding 
and signaling in regulating macrophage function in vitro and in vivo. Front Biosci, 2001. 6: p. 
D992-9. 
128. Franchimont, D., et al., Glucocorticoids and inflammation revisited: The state of the art - NIH 
Clinical Staff Conference. NeuroImmunoModulation, 2002. 10(5): p. 247-260. 
129. Patil, S.D., F. Papadimitrakopoulos, and D.J. Burgess, Dexamethasone-loaded poly(lactic-co-
glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation 
control. Diabetes Technology and Therapeutics, 2004. 6(6): p. 887-897. 
130. Patil, S.D., F. Papadmitrakopoulos, and D.J. Burgess, Concurrent delivery of dexamethasone 
and VEGF for localized inflammation control and angiogenesis. Journal of Controlled 
Release, 2007. 117(1): p. 68-79. 
131. Norton, L.W., et al., Vascular endothelial growth factor and dexamethasone release from 
nonfouling sensor coatings affect the foreign body response. Journal of Biomedical Materials 
Research - Part A, 2007. 81(4): p. 858-869. 
132. Oshikawa, K., H. Yamasawa, and Y. Sugiyama, Human lung fibroblasts inhibit macrophage 
inflammatory protein-1α production by lipopolysaccharide-stimulated macrophages. 
Biochemical and Biophysical Research Communications, 2003. 312(3): p. 650-655. 
133. Vancheri, C., et al., Normal Human Lung Fibroblasts Differently Modulate Interleukin-10 and 
Interleukin-12 Production by Monocytes. American Journal of Respiratory Cell and Molecular 
Biology, 2001. 25(5): p. 592-599. 
134. Chung, A.S. and W.J. Kao, Fibroblasts regulate monocyte response to ECM-derived matrix: 
The effects on monocyte adhesion and the production of inflammatory, matrix remodeling, and 
growth factor proteins. Journal of Biomedical Materials Research Part A, 2009. 89A(4): p. 
841-853. 
135. Scott, J.E., Extracellular matrix, supramolecular organisation and shape. Journal of 
Anatomy, 1995. 187(2): p. 259-269. 
136. Rhodes, J.M. and M. Simons, The extracellular matrix and blood vessel formation: not just a 
scaffold. Journal of Cellular and Molecular Medicine, 2007. 11(2): p. 176-205. 
137. Ottani, V., M. Raspanti, and A. Ruggeri, Collagen structure and functional implications. 
Micron, 2001. 32(3): p. 251-260. 
138. Papagiannopoulos, A., T.A. Waigh, and T.E. Hardingham, The viscoelasticity of self-
assembled proteoglycan combs. Faraday Discussions, 2008. 139: p. 337-357. 
139. Hoffman, A.S., Hydrogels for biomedical applications. Advanced Drug Delivery Reviews, 
2002. 54(1): p. 3-12. 
140. Valentin, J.E., et al., Extracellular matrix bioscaffolds for orthopaedic applications: A 
comparative histologic study. Journal of Bone and Joint Surgery - Series A, 2006. 88(12): p. 
2673-2686. 
141. Nagai, M., et al., In vitro Study of Collagen Coating of Titanium Implants for Initial Cell 
Attachment. Dental Materials Journal, 2002. 21(3): p. 250-260. 
142. Rammelt, S., et al., Coating of titanium implants with type-I collagen. Journal of Orthopaedic 
Research, 2004. 22(5): p. 1025-1034. 
143. Becker, D., et al., Proliferation and differentiation of rat calvarial osteoblasts on type I 
collagen-coated titanium alloy. Journal of Biomedical Materials Research, 2002. 59(3): p. 
516-527. 
144. Nakamura, H.K., et al., A Role for Proteoglycans in Mineralized Tissue-Titanium Adhesion. 
Journal of Dental Research, 2007. 86(2): p. 147-152. 
145. Rammelt, S., et al., Coating of titanium implants with collagen, RGD peptide and chondroitin 
sulfate. Biomaterials, 2006. 27(32): p. 5561-5571. 
APPENDIX 
 
81 
 
146. Rammelt, S., et al., In vivo effects of coating loaded and unloaded Ti implants with collagen, 
chondroitin sulfate, and hydroxyapatite in the sheep tibia. Journal of Orthopaedic Research, 
2007. 25(8): p. 1052-1061. 
147. Witt, D.P. and A.D. Lander, Differential binding of chemokines to glycosaminoglycan 
subpopulations. Current Biology, 1994. 4(5): p. 394-400. 
148. Salek-Ardakani, S., et al., Heparin and heparan sulfate bind interleukin-10 and modulate its 
activity. Blood, 2000. 96(5): p. 1879-1888. 
149. Gristina, A.G., Biomaterial-centered infection: microbial adhesion versus tissue integration. 
Science, 1987. 237(4822): p. 1588-1595. 
150. Savage, D.C. and M. Fletcher, Bacterial Adhesion: Mechanisms and Physiological 
Significance. 1985: Springer. 
151. Sugarman, B. and E.J. Young, Infections Associated With Prosthetic Devices. 1984: CRC 
Press. 
152. Slusher, M.M., et al., Extended-Wear Lenses, Biofilm, and Bacterial Adhesion. Archives of 
Ophthalmology, 1987. 105(1): p. 110-115. 
153. An, Y.H. and R.J. Friedman, Concise review of mechanisms of bacterial adhesion to 
biomaterial surfaces. J Biomed Mater Res, 1998. 43(3): p. 338-48. 
154. Heilmann, C., et al., Evidence for autolysin-mediated primary attachment of Staphylococcus 
epidermidis to a polystyrene surface. Molecular Microbiology, 1997. 24(5): p. 1013-1024. 
155. Foster, S.J., Molecular characterization and functional analysis of the major autolysin of 
Staphylococcus aureus 8325/4. Journal of Bacteriology, 1995. 177(19): p. 5723-5725. 
156. Donaruma, L.G., Surface and interfacial aspects of biomedical polymers. Joseph D. Andrade, 
Ed., Plenum, New York, 1985, 479 pp. Price: $69.50. Journal of Polymer Science Part C: 
Polymer Letters, 1986. 24(8): p. 427-428. 
157. Laverty, G., S.P. Gorman, and B.F. Gilmore, 2 - Biofilms and implant-associated infections, in 
Biomaterials and Medical Device - Associated Infections, L. Barnes and I.R. Cooper, Editors. 
2015, Woodhead Publishing: Oxford. p. 19-45. 
158. Cooper, I.R., 1 - Introduction to biomaterials and medical device-associated infections, in 
Biomaterials and Medical Device - Associated Infections, L. Barnes and I.R. Cooper, Editors. 
2015, Woodhead Publishing: Oxford. p. 3-17. 
159. Vilain, S., et al., DNA as an Adhesin: Bacillus cereus Requires Extracellular DNA To Form 
Biofilms. Applied and Environmental Microbiology, 2009. 75(9): p. 2861-2868. 
160. Mann, E.E., et al., Modulation of eDNA Release and Degradation Affects Staphylococcus 
aureus Biofilm Maturation. PLoS ONE, 2009. 4(6): p. e5822. 
161. Harmsen, M., et al., Role of extracellular DNA during biofilm formation by listeria 
monocytogenes. Applied and Environmental Microbiology, 2010. 76(7): p. 2271-2279. 
162. Daniels, R., J. Vanderleyden, and J. Michiels, Quorum sensing and swarming migration in 
bacteria. FEMS Microbiol Rev, 2004. 28(3): p. 261-89. 
163. Donlan, R.M., Biofilms: microbial life on surfaces. Emerg Infect Dis, 2002. 8(9): p. 881-90. 
164. Swift, S., et al., Quorum sensing as a population-density-dependent determinant of bacterial 
physiology. Adv Microb Physiol, 2001. 45: p. 199-270. 
165. Rutherford, S.T. and B.L. Bassler, Bacterial quorum sensing: its role in virulence and 
possibilities for its control. Cold Spring Harb Perspect Med, 2012. 2(11). 
166. Parsek, M.R. and E.P. Greenberg, Sociomicrobiology: the connections between quorum 
sensing and biofilms. Trends Microbiol, 2005. 13(1): p. 27-33. 
167. Romeo, T., Bacterial Biofilms. 2008: Springer. 
168. Islam, M.S., J.P. Richards, and A.K. Ojha, Targeting drug tolerance in mycobacteria: a 
perspective from mycobacterial biofilms. Expert review of anti-infective therapy, 2012. 10(9): 
p. 1055-1066. 
169. Montanaro, L., et al., Scenery of Staphylococcus implant infections in orthopedics. Future 
Microbiology, 2011. 6(11): p. 1329-1349. 
170. Wilson, S.K. and J.W. Costerton, Biofilm and Penile Prosthesis Infections in the Era of 
Coated Implants: A Review. The Journal of Sexual Medicine, 2012. 9(1): p. 44-53. 
171. Bose, S. and A.K. Ghosh, 4 - Diagnosis of biofilm-associated infections in medical devices, in 
Biomaterials and Medical Device - Associated Infections, L. Barnes and I.R. Cooper, Editors. 
2015, Woodhead Publishing: Oxford. p. 71-82. 
APPENDIX 
 
82 
 
172. Praneenararat, T., A.G. Palmer, and H.E. Blackwell, Chemical methods to interrogate 
bacterial quorum sensing pathways. Organic & Biomolecular Chemistry, 2012. 10(41): p. 
8189-8199. 
173. Rabin, N., et al., Tailor-made LasR agonists modulate quorum sensing in Pseudomonas 
aeruginosa. Organic & Biomolecular Chemistry, 2013. 11(41): p. 7155-7163. 
174. Mattmann, M.E. and H.E. Blackwell, Small Molecules That Modulate Quorum Sensing and 
Control Virulence in Pseudomonas aeruginosa. The Journal of Organic Chemistry, 2010. 
75(20): p. 6737-6746. 
175. Chen, M., Q. Yu, and H. Sun, Novel strategies for the prevention and treatment of biofilm 
related infections. Int J Mol Sci, 2013. 14(9): p. 18488-501. 
176. Rucker, M., et al., Angiogenic and inflammatory response to biodegradable scaffolds in 
dorsal skinfold chambers of mice. Biomaterials, 2006. 27(29): p. 5027-38. 
177. Catelas, I., M.A. Wimmer, and S. Utzschneider, Polyethylene and metal wear particles: 
characteristics and biological effects. Semin Immunopathol, 2011. 33(3): p. 257-71. 
178. Conus, S. and H.U. Simon, Cathepsins and their involvement in immune responses. Swiss 
Med Wkly, 2010. 140: p. w13042. 
179. Park, G.Y., et al., Autotaxin production of lysophosphatidic acid mediates allergic asthmatic 
inflammation. Am J Respir Crit Care Med, 2013. 188(8): p. 928-40. 
180. Pulverer, J.E., et al., Temporal and Spatial Resolution of Type I and III Interferon Responses 
In Vivo. Journal of Virology, 2010. 84(17): p. 8626-8638. 
181. Asano, A., H.K. Jin, and T. Watanabe, Mouse Mx2 gene: organization, mRNA expression and 
the role of the interferon-response promoter in its regulation. Gene, 2003. 306(0): p. 105-113. 
182. Haller, O., P. Staeheli, and G. Kochs, Interferon-induced Mx proteins in antiviral host 
defense. Biochimie, 2007. 89(6–7): p. 812-818. 
183. Mordstein, M., et al., Interferon-λ Contributes to Innate Immunity of Mice against Influenza A 
Virus but Not against Hepatotropic Viruses. PLoS Pathog, 2008. 4(9): p. e1000151. 
184. Decker, T., M. Muller, and S. Stockinger, The yin and yang of type I interferon activity in 
bacterial infection. Nat Rev Immunol, 2005. 5(9): p. 675-87. 
185. Trinchieri, G., Type I interferon: friend or foe? The Journal of Experimental Medicine, 2010. 
207(10): p. 2053-2063. 
186. Lienenklaus, S., et al., Novel reporter mouse reveals constitutive and inflammatory expression 
of IFN-beta in vivo. J Immunol, 2009. 183(5): p. 3229-36. 
187. Perrakis, A. and W.H. Moolenaar, Autotaxin: structure-function and signaling. J Lipid Res, 
2014. 
188. Fleming, T.J., M.L. Fleming, and T.R. Malek, Selective expression of Ly-6G on myeloid 
lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen 
(Gr-1) detects members of the Ly-6 family. J Immunol, 1993. 151(5): p. 2399-408. 
189. Daley, J.M., et al., Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J 
Leukoc Biol, 2008. 83(1): p. 64-70. 
190. Rose, S., A. Misharin, and H. Perlman, A novel Ly6C/Ly6G-based strategy to analyze the 
mouse splenic myeloid compartment. Cytometry. Part A : the journal of the International 
Society for Analytical Cytology, 2012. 81(4): p. 343-350. 
191. DeLeo, F.R., Modulation of phagocyte apoptosis by bacterial pathogens. Apoptosis, 2004. 
9(4): p. 399-413. 
192. Ablasser, A., et al., Nucleic acid driven sterile inflammation. Clinical Immunology, 2013. 
147(3): p. 207-215. 
193. Liu, H., E.B. Slamovich, and T.J. Webster, Less harmful acidic degradation of poly(lactic-co-
glycolic acid) bone tissue engineering scaffolds through titania nanoparticle addition. 
International Journal of Nanomedicine, 2006. 1(4): p. 541-545. 
194. Varde, N.K. and D.W. Pack, Microspheres for controlled release drug delivery. Expert 
Opinion on Biological Therapy, 2004. 4(1): p. 35-51. 
195. Jayakumar, R., et al., Biomaterials based on chitin and chitosan in wound dressing 
applications. Biotechnology Advances, 2011. 29(3): p. 322-337. 
196. Patel, M.P., R.R. Patel, and J.K. Patel, Chitosan mediated targeted drug delivery system: a 
review. J Pharm Pharm Sci, 2010. 13(4): p. 536-57. 
APPENDIX 
 
83 
 
197. Sasaki, Y., et al., Iba1 is an actin-cross-linking protein in macrophages/microglia. Biochem 
Biophys Res Commun, 2001. 286(2): p. 292-7. 
198. Guggenbichler, J.P., et al., Incidence and clinical implication of nosocomial infections 
associated with implantable biomaterials - catheters, ventilator-associated pneumonia, 
urinary tract infections. GMS Krankenhhyg Interdiszip, 2011. 6(1): p. Doc18. 
199. Barrat, F.J., et al., Nucleic acids of mammalian origin can act as endogenous ligands for Toll-
like receptors and may promote systemic lupus erythematosus. The Journal of Experimental 
Medicine, 2005. 202(8): p. 1131-1139. 
200. Kolaczkowska, E. and P. Kubes, Neutrophil recruitment and function in health and 
inflammation. Nat Rev Immunol, 2013. 13(3): p. 159-75. 
201. Hamilton, J.A., GM-CSF in inflammation and autoimmunity. Trends Immunol, 2002. 23(8): p. 
403-8. 
202. Araki, H., et al., Reprogramming of human postmitotic neutrophils into macrophages by 
growth factors. Blood, 2004. 103(8): p. 2973-80. 
203. Sasmono, R.T., et al., Mouse neutrophilic granulocytes express mRNA encoding the 
macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-
specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. 
J Leukoc Biol, 2007. 82(1): p. 111-23. 
204. Tseng, J.-C. and Andrew L. Kung, In Vivo Imaging of Inflammatory Phagocytes. Chemistry & 
Biology, 2012. 19(9): p. 1199-1209. 
205. Gross, S., et al., Bioluminescence imaging of myeloperoxidase activity in vivo. Nature 
medicine, 2009. 15(4): p. 455-461. 
206. Ikeda, Y., et al., Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis 
and the effect of cathepsin B on the activation of pro-urokinase. J Med Invest, 2000. 47(1-2): 
p. 61-75. 
207. Joyce, J.A. and D. Hanahan, Multiple roles for cysteine cathepsins in cancer. Cell Cycle, 
2004. 3(12): p. 1516-619. 
208. Faiz, A., et al., The Expression and Activity of Cathepsins D, H and K in Asthmatic Airways. 
PLoS ONE, 2013. 8(3): p. e57245. 
209. Li, X., et al., Increased expression of cathepsins and obesity-induced proinflammatory 
cytokines in lacrimal glands of male NOD mouse. Invest Ophthalmol Vis Sci, 2010. 51(10): p. 
5019-29. 
210. Hannaford, J., H. Guo, and X. Chen, Involvement of cathepsins B and L in inflammation and 
cholesterol trafficking protein NPC2 secretion in macrophages. Obesity (Silver Spring), 2013. 
21(8): p. 1586-95. 
211. Madan, D., et al., Non-Invasive Imaging of Tumors by Monitoring Autotaxin Activity Using an 
Enzyme-Activated Near-Infrared Fluorogenic Substrate. PLoS ONE, 2013. 8(11): p. e79065. 
212. Lowik, C.W., et al., Whole body optical imaging in small animals and its translation to the 
clinic: intra-operative optical imaging guided surgery. Eur J Cancer, 2009. 45 Suppl 1: p. 
391-3. 
213. Kaijzel, E.L., G. van der Pluijm, and C.W. Lowik, Whole-body optical imaging in animal 
models to assess cancer development and progression. Clin Cancer Res, 2007. 13(12): p. 
3490-7. 
214. Becker, A., et al., Receptor-targeted optical imaging of tumors with near-infrared fluorescent 
ligands. Nat Biotechnol, 2001. 19(4): p. 327-31. 
215. Sato, A., B. Klaunberg, and R. Tolwani, In vivo bioluminescence imaging. Comp Med, 2004. 
54(6): p. 631-4. 
216. Thompson, J.F., L.S. Hayes, and D.B. Lloyd, Modulation of firefly luciferase stability and 
impact on studies of gene regulation. Gene, 1991. 103(2): p. 171-7. 
217. Rais, B., et al., Animal Test Models for Implant-Associated Inflammation and Infections, in 
Biomedical Technology, T. Lenarz and P. Wriggers, Editors. 2015, Springer International 
Publishing. p. 175-187. 
218. Youn, H. and K.-J. Hong, In Vivo Non Invasive Molecular Imaging for Immune Cell Tracking 
in Small Animals. Immune Network, 2012. 12(6): p. 223-229. 
219. Makadia, H.K. and S.J. Siegel, Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable 
Controlled Drug Delivery Carrier. Polymers, 2011. 3(3): p. 1377-1397. 
APPENDIX 
 
84 
 
220. Sung, H.-J., et al., The effect of scaffold degradation rate on three-dimensional cell growth 
and angiogenesis. Biomaterials, 2004. 25(26): p. 5735-5742. 
221. Hickey, T., et al., Dexamethasone/PLGA microspheres for continuous delivery of an anti-
inflammatory drug for implantable medical devices. Biomaterials, 2002. 23(7): p. 1649-56. 
222. Lee, H., et al., Fabrication and characteristics of anti-inflammatory magnesium hydroxide 
incorporated PLGA scaffolds formed with various porogen materials. Macromolecular 
Research, 2014. 22(2): p. 210-218. 
223. AFFAIRS, A.C.O.S., Titanium applications in dentistry. The Journal of the American Dental 
Association, 2003. 134(3): p. 347-349. 
224. Jorge, J., et al., Titanium in Dentistry: Historical Development, State of the Art and Future 
Perspectives. The Journal of Indian Prosthodontic Society, 2013. 13(2): p. 71-77. 
225. Staiger, M.P., et al., Magnesium and its alloys as orthopedic biomaterials: A review. 
Biomaterials, 2006. 27(9): p. 1728-1734. 
226. Saris, N.E., et al., Magnesium. An update on physiological, clinical and analytical aspects. 
Clin Chim Acta, 2000. 294(1-2): p. 1-26. 
227. Badar, M., et al., The formation of an organic coat and the release of corrosion microparticles 
from metallic magnesium implants. Acta Biomaterialia, 2013. 9(7): p. 7580-7589. 
228. Saralidze, K., L.H. Koole, and M.L.W. Knetsch, Polymeric Microspheres for Medical 
Applications. Materials, 2010. 3(6): p. 3537-3564. 
229. Rinaudo, M., Chitin and chitosan: Properties and applications. Progress in Polymer Science, 
2006. 31(7): p. 603-632. 
230. Bueter, C.L., et al., Chitosan but not chitin activates the inflammasome by a mechanism 
dependent upon phagocytosis. J Biol Chem, 2011. 286(41): p. 35447-55. 
231. Bueter, C.L., et al., Spectrum and mechanisms of inflammasome activation by chitosan. J 
Immunol, 2014. 192(12): p. 5943-51. 
232. Ertel, W., et al., Circulating mediators in serum of injured patients with septic complications 
inhibit neutrophil apoptosis through up-regulation of protein-tyrosine phosphorylation. J 
Trauma, 1998. 44(5): p. 767-75; discussion 775-6. 
233. Matute-Bello, G., et al., Neutrophil apoptosis in the acute respiratory distress syndrome. Am J 
Respir Crit Care Med, 1997. 156(6): p. 1969-77. 
234. Brown, V., et al., Dysregulated apoptosis and NFkappaB expression in COPD subjects. 
Respir Res, 2009. 10: p. 24. 
235. Milot, E. and J.G. Filep, Regulation of Neutrophil Survival/Apoptosis by Mcl-1. 
TheScientificWorldJournal, 2011. 11: p. 1948-1962. 
236. Tak, T., et al., What's your age again? Determination of human neutrophil half-lives revisited. 
J Leukoc Biol, 2013. 94(4): p. 595-601. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
85 
 
10. Acknowledgements 
 
I would like to sincerely express my gratitude to my supervisor Prof. Dr. Peter P. Müller without 
whom this thesis would not be possible. I am deeply indebted to him for guidance and support at all 
times of research and writing of this thesis. I would like to thank my thesis committee member Dr. 
Hansjörg Hauser for his stimulating suggestions and critical reason of data. I would like to express my 
appreciation to Dr. Stefan Lienenklaus for his expertise in in vivo optical imaging and also for his 
insightful suggestions. I would like to thank our collaborator and my thesis committee member Prof. 
Dr. Peter Behrens for his support in project. I would also like to thank Dr. Mario Köster for providing 
me transgenic mice to carry out my experiments. I am thankful to Dr. Maria Höxter for performing 
FACS sorting experiments. I must appreciate Dr. Marina Pils for performing histology and also 
helping in interpretation of data. I would also like to thank Dr. Mark Brönstrup for a huge support in 
funding last experiments of my research. I must acknowledge Dr. Haiyu Hu, Dr. Verena Fetz and 
Kevin Ferreira in synthesis and characterization of siderophore compounds. My appreciation to Dr. 
Sabine Kirchoff, Dr. Berenike, Daniela Romke and rest of graduate school for providing outstanding 
support to graduate students. A special thanks to Dr. Upneet Hillebrand, Dr. Sharmila Nair and Dr. 
Marcin Cebula for helping me in my experimental design and FACS experiments. I must thank Dr. 
Christoph Lipps for his suggestions and support. I would also like to thank my lab-mate Muhammad 
Imran Rahim for being supportive at all times. I must thank Danim, Neha, Petra, Tharini, Sripriya, 
Shiwani and Niharika for being dependable friends.  
 
At the end, I would like to thank my family for their unconditional support and love. My heartfelt 
thanks goes to Hameeda Khatoon for her selfless love and support. I would also like to thank Faisal 
Anees for being so supportive and patient with me. 
Summary
Highlights
Experience
BUSHRA RAIS
Militschstrasse 38, Braunschweig, Germany 38124 | C: +49 (0) 15785279733 | Bushra.Rais@helmholtz-hzi.de
Research Biologist with five years in laboratory research
Expertise in cell culture and animal experiments.
Accomplished in generating and applying new protocols and technologies.
Versed in organizing, writing and editing detailed reports and research papers.
 
Animal handling (FELASA B
certified)
In vivo optical imaging
Sterile surgery in mice
Cell culture expertise ( including
BMDMs, neutrophils and
conditionally immortalised cells)
Confocal microscopy
Flow cytometery
Quantitative PCR
Immunohistochemistry
Nucleic Acids Isolation
Fluent in English
Skilled scientific writing
Data analysis and presentation skills
Good scientific practice
Strong communication skills
Ability to expand collaborations
Sep 2012 to CurrentPhD
Helmholtz Centre for Infection Research - Braunschweig
Designed and conducted experiments to achieve research objectives.
Established novel in vitro and in vivo biological test systems to study the interaction of
biomaterials with cells and tissues.
Managed the mouse experiments independently and coordinated the weekly ordering
and housing of mice
Identified the  advantage of  conditionally  immortalized cells  in  the  cell-material
interface studies
 
 
Dec 2011 to Jun 2012Research Assistant
Kings College London - London
Assisted in qPCR experiments for the running project
Extracted RNA from various organs of the rainbow trout fish
Conducted cloning related experiments
Designed and checked primers
Developed competent cells for transformation experiments
Jan 2011 to Jul 2011Master's research project
Kings College London - London
Studied the transcriptional profile of a cardiovascular disorder, Deep Venous
Thrombosis (DVT)
Gained experience in qPCR and immunohistochemistry.
Analysed and presented the data in simplified text and illustrated graphs
Education
Publications
External presentations
2011Master of Science, Biomedical and Molecular Sciences Research
Kings College London - London, United Kingdom
Graduated with merit.
2009Bachelor of technology, Biotechnology
Amity University - Lucknow, India
Graduated with distinction
Received 'Gold medal' for being excellent in academics
Rais B, et al. Animal Test Models for Implant-Associated Inflammation and Infections.
Biomedical Technology.74: Springer International Publishing; 2015. p. 175-87.
 
Rahim  M.I.,  Eifler  R.,  Rais  B.  and  Müller,  P.P.  Alkalization  is  responsible  for
antibacterial  effects  of  corroding  magnesium.  Journal  of  Biomedical  Materials
Research Part A. 2015.
 
Rais B, et al. Novel strategy to detect implant-related inflammation or infection.
Manuscript in preparation. 
Rais  B.  and  Müller  P.P.,  Animal  model  for  monitoring  biomaterial  associated
inflammation or infection. Talk. Annual meeting of the Scandinavian Society for
Biomaterials- Latvia. May 6–8th, 2015.
 
Rais B., Rahim M.I., Guledani A., and Müller P.P., Real time imaging of cells, tissue
and bacteria. Talk. Annual Retreat – Helmholtz Centre for Infection Research- Goslar.
May 20th-22nd, 2015
 
Rais B., and Müller P.P., In vivo imaging of biomaterial associated inflammation and
infection.  Talk.  Progress  Seminar  –  Helmholtz  Centre  for  Infection  Research-
Braunschweig. March 20, 2014
 
Rais B., Tolle C., Köster M., Hauser H. and Müller P.P., In vivo imaging of biomaterial
associated inflammation or infection. Poster. BMT – 48th DGBMT Annual Conference –
Hannover. October 8-10th, 2014.
 
Rais B. and Müller P.P., Quantification of biomaterial associated inflammation and
infection. Poster. 7th International PhD symposium- Helmholtz Centre for Infection
Research. December 11, 2014
 
Rais B. and Müller P.P., Development of biological test systems to study interactions
of novel implant materials with cells, tissues and bacteria. Poster. 6th International
PhD symposium- Helmholtz Centre for Infection Research. December 12, 2013.
 
Rais B., Rahim M.I. and Müller P.P., In vitro and in vivo biocompatibility testing of
medical  implants.  Poster.  International  Conference  on  Biomedical  technology  -
Hannover. November 20th-22nd, 2013.
 
Rais B. and Müller P.P., In vivo and in vitro evaluation of implant biocompatibility.
Poster. Annual Retreat – Helmholtz Centre for Infection Research- Bad Bevensen.
June 13th-14th, 2013
References
1. Prof. Dr. Peter P. Müller
Group Leader - Chemical Biology Department
Helmholtz-Zentrum für Infektionsforschung Inhoffenstraße 7
38124 Braunschweig, Germany
Tel.: +49 (0) 531-6181-5070
Fax: +49 (0) 531-6181-5002
Email: Peter.Müller@helmholtz-hzi.de
2. Dr. Hansjörg Hauser
Head of Department
Gene Regulation and Differentiation
Helmholtz-Zentrum für Infektionsforschung Inhoffenstraße 7
38124 Braunschweig, Germany
Tel.: +49 (0) 531-6181-5000
Fax: +49 (0) 531-6181-500
Email: Hansjoerg.Hauser@helmholtz-hzi.de
